2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary

Edmond M. Cronin, MB, BCh, BAO, FHRS, CCDS, CEPS-A (Chair),[1]
Frank M. Bogun, MD (Vice-Chair),[2] Philippe Maury, MD (EHRA Chair),[3]
Petr Peichl, MD, PhD (EHRA Vice-Chair),[4] Minglong Chen, MD, PhD, FHRS (APHRS Chair),[5]
Narayanan Namboodiri, MBBS, MD (APHRS Vice-Chair),[6]
Luis Aguinaga, MD, PhD, FESC, FACC (LAHRS Chair),[7]
Luiz Roberto Leite, MD, PhD, FHRS (LAHRS Vice-Chair),[8]
Sana M. Al-Khatib, MD, MHS, FHRS, CCDS,[9] Elad Anter, MD,[10]
Antonio Berruezo, MD, PhD,[11,*] David J. Callans, MD, FHRS, CCDS,[12]
Mina K. Chung, MD, FHRS,[13,†] Phillip Cuculich, MD,[14] Andre d'Avila, MD, PhD,[15,‡]
Barbara J. Deal, MD, FACC,[16,§] Paolo Della Bella, MD,[17,*]
Thomas Deneke, MD, PhD, FHRS,[18,*] Timm-Michael Dickfeld, MD, PhD, FACC, FHRS,[19]
Claudio Hadid, MD,[20,¶] Haris M. Haqqani, MBBS, PhD, FHRS,[21,#] G. Neal Kay, MD, CCDS,[22]
Rakesh Latchamsetty, MD, FHRS,[2] Francis Marchlinski, MD, FHRS,[12]
John M. Miller, MD, FHRS,[23,†] Akihiko Nogami, MD, PhD,[24,**]
Akash R. Patel, MD, FHRS, CEPS-P,[25,††] Rajeev Kumar Pathak, MBBS, PhD, FHRS,[26,#]
Luis C. Saenz Morales, MD,[27,¶] Pasquale Santangeli, MD, PhD,[12]
John L. Sapp Jr., MD, FHRS,[28] Andrea Sarkozy, MD, PhD, FEHRA,[29,*]
Kyoko Soejima, MD,[30,#] William G. Stevenson, MD, FHRS,[31]
Usha B. Tedrow, MD, MS, FHRS,[32] Wendy S. Tzou, MD, FHRS,[33] Niraj Varma, MD, PhD,[13]
Katja Zeppenfeld, MD, PhD, FESC, FEHRA[34,*]

Document Reviewers: Samuel J. Asirvatham, MD, FHRS; Eduardo Back Sternick, MD, PhD; Janice Chyou, MD; Sabine Ernst, MD, PhD; Guilherme Fenelon, MD, PhD; Edward P. Gerstenfeld, MD, MS, FACC; Gerhard Hindricks, MD; Koichi Inoue, MD, PhD; Jeffrey J. Kim, MD; Kousik Krishnan, MD, FHRS, FACC; Karl-Heinz Kuck, MD, FHRS; Martin Ortiz Avalos, MD; Thomas Paul, MD, FACC, FHRS; Mauricio I. Scanavacca, MD, PhD; Roderick Tung, MD, FHRS; Jamie Voss, MBChB; Takumi Yamada, MD; Teiichi Yamane, MD, PhD, FHRS

From the [1]Hartford Hospital, Hartford, Connecticut, [2]University of Michigan, Ann Arbor, Michigan, [3]University Hospital Rangueil, Toulouse, France, [4]Institute for Clinical and Experimental Medicine, Prague, Czech Republic, [5]Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, [6]Sree Chitra Institute for Medical Sciences and Technology, Thiruvananthapuram, India, [7]Centro Privado de Cardiología, Tucuman, Argentina, [8]Instituto Brasília de Arritmia, Brasília, Brazil, [9]Duke University Medical Center, Durham, North Carolina, [10]Beth Israel Deaconess Medical Center, Boston, Massachusetts, [11]Heart Institute, Teknon Medical Center, Barcelona, Spain, [12]University of Pennsylvania, Philadelphia, Pennsylvania, [13]Cleveland Clinic, Cleveland, Ohio, [14]Washington University School of Medicine, St. Louis, Missouri, [15]Hospital Cardiologico SOS Cardio, Florianopolis, Brazil, [16]Northwestern University Feinberg School of Medicine, Chicago, Illinois, [17]Ospedale San Raffaele, Milan, Italy, [18]Herz- und Gefäß-Klinik, Bad Neustadt, Germany, [19]University of Maryland, Baltimore, Maryland, [20]Hospital General de Agudos Cosme Argerich, Buenos Aires, Argentina, [21]University of Queensland, The Prince Charles Hospital,

1547-5271/$-see front matter © 2019 The Heart Rhythm Society; the European Heart Rhythm Association, a registered branch of the European Society of Cardiology; the Asia Pacific Heart Rhythm Society; and the Latin American Heart Rhythm Society. Published by Elsevier Inc./Oxford University Press/Wiley. This article is published under the Creative Commons CC-BY license.

https://doi.org/10.1016/j.hrthm.2019.03.014

Chermside, Australia, [22]*University of Alabama at Birmingham, Birmingham, Alabama,* [23]*Indiana University School of Medicine, Krannert Institute of Cardiology, Indianapolis, Indiana,* [24]*University of Tsukuba, Ibaraki, Japan,* [25]*University of California San Francisco Benioff Children's Hospital, San Francisco, California,* [26]*Australian National University, Canberra Hospital, Canberra, Australia,* [27]*CardioInfantil Foundation, Cardiac Institute, Bogota, Columbia,* [28]*Queen Elizabeth II Health Sciences Centre, Halifax, Canada,* [29]*University Hospital Antwerp, University of Antwerp, Antwerp, Belgium,* [30]*Kyorin University School of Medicine, Tokyo, Japan,* [31]*Vanderbilt University Heart and Vascular Center, Nashville, Tennessee,* [32]*Brigham and Women's Hospital, Boston, Massachusetts,* [33]*University of Colorado Denver, Aurora, Colorado, and* [34]*Leiden University Medical Center, Leiden, the Netherlands.*

*Representative of the European Heart Rhythm Association (EHRA)
†Representative of the American College of Cardiology (ACC)
‡Representative of the Sociedade Brasileira de Arritmias Cardíacas (SOBRAC)
§Representative of the American Heart Association (AHA)
¶Representative of the Latin American Heart Rhythm Society (LAHRS)
#Representative of the Asia Pacific Heart Rhythm Society (APHRS)
**Representative of the Japanese Heart Rhythm Society (JHRS)
††Representative of the Pediatric and Congenital Electrophysiology Society (PACES)

ABSTRACT

Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular complexes to sustained ventricular tachycardia and fibrillation. Rapid developments have taken place over the past decade in our understanding of these arrhythmias and in our ability to diagnose and treat them. The field of catheter ablation has progressed with the development of new methods and tools, and with the publication of large clinical trials. Therefore, global cardiac electrophysiology professional societies undertook to outline recommendations and best practices for these procedures in a document that will update and replace the 2009 *EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias*. An expert writing group, after reviewing and discussing the literature, including a systematic review and meta-analysis published in conjunction with this document, and drawing on their own experience, drafted and voted on recommendations and summarized current knowledge and practice in the field. Each recommendation is presented in knowledge byte format and is accompanied by supportive text and references. Further sections provide a practical synopsis of the various techniques and of the specific ventricular arrhythmia sites and substrates encountered in the electrophysiology lab. The purpose of this document is to help electrophysiologists around the world to appropriately select patients for catheter ablation, to perform procedures in a safe and efficacious manner, and to provide follow-up and adjunctive care in order to obtain the best possible outcomes for patients with ventricular arrhythmias.

KEYWORDS Catheter ablation; Clinical document; Electrical storm; Electroanatomical mapping; Electrocardiogram; Expert consensus statement; Imaging; Premature ventricular complex; Radiofrequency ablation; Ventricular arrhythmia; Ventricular tachycardia

ABBREVIATIONS **AAD** = antiarrhythmic drug; **AIV** = anterior interventricular vein; **AMC** = aortomitral continuity; **ARVC** = arrhythmogenic right ventricular cardiomyopathy; **ATP** = antitachycardia pacing; **AV** = atrioventricular; **BBRVT** = bundle branch reentrant ventricular tachycardia; **CHD** = congenital heart disease; **CMR** = cardiac magnetic resonance imaging; **COR** = class of recommendation; **CS** = coronary sinus; **DCM** = dilated cardiomyopathy; **EAM** = electroanatomical mapping; **ECG** = electrocardiogram; **GCV** = great cardiac vein; **HCM** = hypertrophic cardiomyopathy; **HS** = hemodynamic support; **ICD** = implantable cardioverter defibrillator; **ICE** = intracardiac echocardiography; **ICM** = ischemic cardiomyopathy; **IHD** = ischemic heart disease; **LBB** = left bundle branch; **LBBB** = left bundle branch block; **LMNA** = lamin A/C; **LOE** = level of evidence; **LSV** = left sinus of Valsalva; **LV** = left ventricle; **LVOT** = left ventricular outflow tract; **NCSV** = noncoronary sinus of Valsalva; **NICM** = nonischemic cardiomyopathy; **PES** = programmed electrical stimulation; **PVC** = premature ventricular complex; **RBB** = right bundle branch; **RBBB** = right bundle branch block; **RSV** = right sinus of Valsalva; **RV** = right ventricle; **RVOT** = right ventricular outflow tract; **RWI** = relationship with industry and other entities; **SHD** = structural heart disease; **SV** = sinus of Valsalva; **VA** = ventricular arrhythmia; **VF** = ventricular fibrillation; **VT** = ventricular tachycardia (Heart Rhythm 2020;17:e155–e205)

Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Developed in collaboration with and endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Japanese Heart Rhythm Society (JHRS), the Pediatric and Congenital Electrophysiology Society (PACES), and the Sociedade Brasileira de Arritmias Cardíacas (SOBRAC). Endorsed by the Canadian Heart Rhythm Society. For copies of this document, please contact the Elsevier Inc. Reprint Department (reprints@elsevier.com). Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the Heart Rhythm Society. Instructions for obtaining permission are located at https://www.elsevier.com/about/our-business/policies/copyright/permissions. Correspondence: Heart Rhythm Society, 1325 G Street NW, Suite 400, Washington, DC 20005. E-mail address: clinicaldocs@hrsonline.org.

TABLE OF CONTENTS

Section 1 Introduction e158
1.1. Document Scope and Rationale e158
1.2. Methods e158
Section 2 Background e160
Section 3 Clinical Evaluation e163
3.1. Clinical Presentation e163
3.2. Diagnostic Evaluation e163
3.2.1. Resting 12-Lead Electrocardiogram e163
3.2.2. Assessment of Structural Heart Disease and Myocardial Ischemia .. e164
3.2.3. Risk Stratification in the Setting of Frequent Premature Ventricular Complexes e164
3.2.4. Longitudinal Follow-up in the Setting of Frequent Premature Ventricular Complexes e165
Section 4 Indications for Catheter Ablation e165
4.1. Idiopathic Outflow Tract Ventricular Arrhythmia e165
4.2. Idiopathic Nonoutflow Tract Ventricular Arrhythmia e166
4.3. Premature Ventricular Complexes With or Without Left Ventricular Dysfunction e168
4.4. Ventricular Arrhythmia in Ischemic Heart Disease e169
4.5. Nonischemic Cardiomyopathy e170
4.6. Ventricular Arrhythmia Involving the His-Purkinje System, Bundle Branch Reentrant Ventricular Tachycardia, and Fascicular Ventricular Tachycardia e171
4.7. Congenital Heart Disease e172
4.8. Inherited Arrhythmia Syndromes e173
4.9. Ventricular Arrhythmia in Hypertrophic Cardiomyopathy e174
Section 5 Procedural Planning e174
Section 6 Intraprocedural Patient Care e176
6.1. Anesthesia e177
6.2. Vascular Access e177
6.3. Epicardial Access e177
6.4. Intraprocedural Hemodynamic Support e178
6.5. Intraprocedural Anticoagulation e178
Section 7 Electrophysiological Testing e179
Section 8 Mapping and Imaging Techniques e179
8.1. Overview e179
8.2. Substrate Mapping in Sinus Rhythm e180
8.3. Intraprocedural Imaging During Catheter Ablation of Ventricular Arrhythmias e180
8.4. Electroanatomical Mapping Systems and Robotic Navigation e181
Section 9 Mapping and Ablation e182
9.1. Ablation Power Sources and Techniques e182
9.2. Idiopathic Outflow Tract Ventricular Arrhythmia e182
9.3. Idiopathic Nonoutflow Tract Ventricular Arrhythmia e183
9.4. Bundle Branch Reentrant Ventricular Tachycardia and Fascicular Ventricular Tachycardia e184
9.5. Postinfarction Ventricular Tachycardia e184
9.6. Dilated Cardiomyopathy e188
9.7. Ventricular Tachycardia Ablation in Hypertrophic Cardiomyopathy e188
9.8. Brugada Syndrome e188
9.9. Polymorphic Ventricular Tachycardia/ Ventricular Fibrillation Triggers e188
9.10. Arrhythmogenic Right Ventricular Cardiomyopathy e189
9.11. Mapping and Ablation in Congenital Heart Disease e190
9.12. Sarcoidosis e191
9.13. Chagas Disease e192
9.14. Miscellaneous Diseases and Clinical Scenarios With Ventricular Tachycardia ... e193
9.15. Surgical Therapy e193
9.16. Sympathetic Modulation e193
9.17. Endpoints of Catheter Ablation of Ventricular Tachycardia e193
Section 10 Postprocedural Care e193
10.1. Postprocedural Care: Access, Anticoagulation, Disposition e194
10.1.1. Postprocedural Care: Access e194
10.1.2. Postprocedural Care: Anticoagulation e194
10.2. Incidence and Management of Complications e197
10.3. Hemodynamic Deterioration and Proarrhythmia e198
10.4. Follow-up of Patients Post Catheter Ablation of Ventricular Tachycardia e199
Section 11 Training and Institutional Requirements and Competencies e199
11.1. Training Requirements and Competencies for Catheter Ablation of Ventricular Arrhythmias e200
11.2. Institutional Requirements for Catheter Ablation of Ventricular Tachycardia e200
Section 12 Future Directions e200
Appendix 1 Author Disclosure Table e201
Appendix 2 Reviewer Disclosure Table e204

Section 1 Introduction

1.1. Document Scope and Rationale

The field of electrophysiology has undergone rapid progress in the last decade, with advances both in our understanding of the genesis of ventricular arrhythmias (VAs) and in the technology used to treat them. In 2009, a joint task force of the European Heart Rhythm Association (EHRA) and the Heart Rhythm Society (HRS), in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA), produced an expert consensus document that outlined the state of the field and defined the indications, techniques, and outcome measures of VA ablation (S1.1.1). In light of advances in the treatment of VAs in the interim, and the growth in the number of VA ablations performed in many countries and regions (S1.1.2,S1.1.3), an updated document is needed. This effort represents a worldwide partnership between transnational cardiac electrophysiology societies, namely, HRS, EHRA, the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS), and collaboration with ACC, AHA, the Japanese Heart Rhythm Society (JHRS), the Brazilian Society of Cardiac Arrhythmias (Sociedade Brasileira de Arritmias Cardíacas [SOBRAC]), and the Pediatric and Congenital Electrophysiology Society (PACES). The consensus statement was also endorsed by the Canadian Heart Rhythm Society (CHRS).

This clinical document is intended to supplement, not replace, the *2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death* (S1.1.4) and the *2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death* (S1.1.5). The scope of the current document relates to ablation therapy for VAs, from premature ventricular complexes (PVCs) to monomorphic and polymorphic ventricular tachycardia (VT) and triggers of ventricular fibrillation (VF). Due to its narrower scope, the consensus statement delves into greater detail with regard to indications and technical aspects of VA ablation than the above-mentioned guidelines.

Where possible, the recommendations in this document are evidence based. It is intended to set reasonable standards that can be applicable worldwide, while recognizing the different resources, technological availability, disease prevalence, and health care delivery logistics in various parts of the world. In addition, parts of this document, particularly Section 9, present a practical guide on how to accomplish the procedures described in a manner that reflects the current standard of care, while recognizing that some procedures are better performed, and some disease states better managed, in settings in which there is specific expertise.

References

S1.1.1. Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS expert consensus on catheter ablation of ventricular arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 2009;6:886–933.

S1.1.2. Hosseini SM, Rozen G, Saleh A, et al. Catheter ablation for cardiac arrhythmias: utilization and in-hospital complications, 2000 to 2013. JACC Clin Electrophysiol 2017;3:1240–1248.

S1.1.3. Raatikainen MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H, Camm J. A decade of information on the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2017 report from the European Heart Rhythm Association. Europace 2017;19(Suppl. 2):ii1–ii90.

S1.1.4. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018;15:e73–e189.

S1.1.5. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al; Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Europace 2015;17:1601–1687.

1.2. Methods

The writing group was selected according to each society's procedures, including content and methodology experts representing the following organizations: HRS, EHRA, APHRS, LAHRS, ACC, AHA, JHRS, PACES, and SOBRAC. Each partner society nominated a chair and co-chair, who did not have relevant relationships with industry and other entities (RWIs). In accordance with HRS policies, disclosure of any RWIs was required from the writing committee members (Appendix 1) and from all peer reviewers (Appendix 2). Of the 38 committee members, 17 (45%) had no relevant RWIs. Recommendations were drafted by the members who did not have relevant RWIs. Members of the writing group conducted comprehensive literature searches of electronic databases, including Medline (via PubMed), Embase, and the Cochrane Library. Evidence tables were constructed to summarize the retrieved studies, with nonrandomized observational designs representing the predominant form of evidence (Appendix 3). Case reports were not used to support recommendations. Supportive text was drafted in the "knowledge byte" format for each recommendation. The writing committee discussed all recommendations and the evidence that informed them before voting. Initial failure to reach consensus was resolved by subsequent discussions, revisions as needed, and re-voting. Although the consensus threshold was set at 67%, all recommendations were approved by at least 80% of the writing committee members. The mean consensus over all recommendations was 95%. A quorum of two-thirds of the writing committee was met for all votes (S1.2.1).

Each recommendation in this document was assigned a Class of Recommendation (COR) and a Level of Evidence (LOE) according to the system developed by ACC and AHA (Table 1) (S1.2.2). The COR denotes the strength of the recommendation based on a careful assessment of the estimated benefits and risks; COR I indicates that the benefit of an intervention far exceeds its risk; COR IIa indicates that the benefit of the intervention moderately exceeds the risk; COR IIb indicates that the benefit may not exceed the risk; and COR III indicates that the benefit is equivalent to or is exceeded by the risk. The LOE reflects the quality of the evidence that supports the recommendation. LOE A is derived from high-quality randomized

controlled trials; LOE B-R is derived from moderate-quality randomized controlled trials; LOE B-NR is derived from well-designed nonrandomized studies; LOE C-LD is derived from randomized or nonrandomized studies with limitations of design or execution; and LOE C-EO indicates that a recommendation was based on expert opinion (S1.2.2).

Unique to this consensus statement is the systematic review commissioned specifically for this document as part of HRS's efforts to adopt the rigorous methodology required for guideline development. The systematic review was performed by an experienced evidence-based practice committee based at the University of Connecticut, which examined the question of VT ablation vs control in patients with VT and ischemic heart disease (IHD) (S1.2.3). The question, in PICOT format, was as follows: In adults with history of sustained VT and IHD, what is the effectiveness and what are the detriments of catheter ablation compared with other interventions? Components of the PICOT were as follows: P = adults with history of sustained VT and IHD; I = catheter ablation; C = control (no therapy or antiarrhythmic drug [AAD]); O = outcomes of interest, which included 1) appropriate implantable cardioverter defibrillator (ICD) therapies (ICD shock or antitachycardia pacing [ATP]), 2) appropriate ICD shocks, 3) VT storm (defined as three shocks within 24 hours), 4) recurrent VT/VF, 5) cardiac hospitalizations, and 6) all-cause mortality; and T = no time restrictions.

Table 1 ACC/AHA Recommendation System: Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, and Diagnostic Testing in Patient Care*

CLASS (STRENGTH) OF RECOMMENDATION	
CLASS I (STRONG)	**Benefit >>> Risk**
Suggested phrases for writing recommendations: ■ Is recommended ■ Is indicated/useful/effective/beneficial ■ Should be performed/administered/other ■ Comparative-Effectiveness Phrases†: ○ Treatment/strategy A is recommended/indicated in preference to treatment B ○ Treatment A should be chosen over treatment B	
CLASS IIa (MODERATE)	**Benefit >> Risk**
Suggested phrases for writing recommendations: ■ Is reasonable ■ Can be useful/effective/beneficial ■ Comparative-Effectiveness Phrases†: ○ Treatment/strategy A is probably recommended/indicated in preference to treatment B ○ It is reasonable to choose treatment A over treatment B	
CLASS IIb (WEAK)	**Benefit ≥ Risk**
Suggested phrases for writing recommendations: ■ May/might be reasonable ■ May/might be considered ■ Usefulness/effectiveness is unknown/unclear/uncertain or not well established	
CLASS III: No Benefit (MODERATE) *(Generally, LOE A or B use only)*	**Benefit = Risk**
Suggested phrases for writing recommendations: ■ Is not recommended ■ Is not indicated/useful/effective/beneficial ■ Should not be performed/administered/other	
CLASS III: Harm (STRONG)	**Risk > Benefit**
Suggested phrases for writing recommendations: ■ Potentially harmful ■ Causes harm ■ Associated with excess morbidity/mortality ■ Should not be performed/administered/other	

LEVEL (QUALITY) OF EVIDENCE‡	
LEVEL A	
■ High-quality evidence‡ from more than 1 RCTs ■ Meta-analyses of high-quality RCTs ■ One or more RCTs corroborated by high-quality registry studies	
LEVEL B-R	**(Randomized)**
■ Moderate-quality evidence‡ from 1 or more RCTs ■ Meta-analyses of moderate-quality RCTs	
LEVEL B-NR	**(Nonrandomized)**
■ Moderate-quality evidence‡ from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies ■ Meta-analyses of such studies	
LEVEL C-LD	**(Limited Data)**
■ Randomized or nonrandomized observational or registry studies with limitations of design or execution ■ Meta-analyses of such studies ■ Physiological or mechanistic studies in human subjects	
LEVEL C-EO	**(Expert Opinion)**
Consensus of expert opinion based on clinical experience	

COR and LOE are determined independently (any COR may be paired with any LOE).

A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).

† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

‡ The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.

Reproduced with permission of the American College of Cardiology (ACC) and the American Heart Association (AHA) (S1.2.2).

An industry forum was conducted to achieve a structured dialogue to address technical questions and to gain a better understanding of future directions and challenges. Because of the potential for actual or perceived bias, HRS imposes strict parameters on information sharing to ensure that industry participates only in an advisory capacity and has no role in either the writing of the document or its review.

The draft document underwent review by the HRS Scientific and Clinical Documents Committee and was approved by the writing committee. Recommendations were subject to a period of public comment, and the entire document underwent rigorous peer review by each of the participating societies and revision by the Chairs, before endorsement.

References

S1.2.1. Indik JH, Patton KK, Beardsall M, et al. HRS clinical document development methodology manual and policies: executive summary. Heart Rhythm 2017;14:e495–e500.

S1.2.2. Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;67:1572–1574.

S1.2.3. Martinez BK, Baker WL, Konopka A, et al. Systematic review and meta-analysis of catheter ablation of ventricular tachycardia in ischemic heart disease. Heart Rhythm 2019 May 10 [Epub ahead of print].

Section 2 Background

This section reviews the history of VT ablation, details the mechanisms of VT, and provides definitions of frequently used terms (Table 2), including anatomic definitions (Table 3), as well as illustrating some types of sustained VA (Figure 1).

Table 2 Definitions

Clinical Characteristics

***Clinical ventricular tachycardia (VT)*:** VT that has occurred spontaneously based on analysis of 12-lead electrocardiogram (ECG) QRS morphology.
***Hemodynamically unstable VT*:** causes hemodynamic compromise requiring prompt termination.
***Idiopathic VT*:** used to indicate VT that is known to occur in the absence of clinically apparent structural heart disease (SHD).
***Idioventricular rhythm*:** three or more consecutive beats at a rate of up to 100 per minute that originate from the ventricles independent of atrial or atrioventricular (AV) nodal conduction. Although various arbitrary rates have been used to distinguish it from VT, the mechanism of ventricular rhythm is more important than the rate. Idioventricular rhythm can be qualified as "accelerated" when the rate exceeds 40 bpm.
***Incessant VT*:** continuous sustained VT that recurs promptly despite repeated intervention for termination over several hours.
***Nonclinical VT*:** VT induced by programmed electrical stimulation (PES) that has not been documented previously.
***Nonsustained VT*:** terminates spontaneously within 30 seconds.
***PVC*:** premature ventricular complex; it is an early ventricular depolarization with or without mechanical contraction. We recommend avoiding the use of the terms "ventricular premature depolarization" and "premature ventricular contraction" to standardize the literature and acknowledge that early electrical activity does not necessarily lead to mechanical contraction.
***Presumptive clinical VT*:** similar to a spontaneous VT based on rate, limited ECG, or electrogram data available from ICD interrogation, but without the 12-lead ECG documentation of spontaneous VT.
***PVC burden*:** the amount of ventricular extrasystoles, preferably reported as the % of beats of ventricular origin of the total amount of beats over a 24-hour recording period.
***Repetitive monomorphic VT*:** continuously repeating episodes of self-terminating nonsustained VT.
***Sustained VT*:** continuous VT for 30 seconds, or which requires an intervention for termination (such as cardioversion).
***VT*:** a tachycardia (rate >100 bpm) with 3 or more consecutive beats that originates from the ventricles independent of atrial or AV nodal conduction.
***VT storm*:** three or more separate episodes of sustained VT within 24 hours, each requiring termination by an intervention.

VT Morphologies

***Monomorphic VT*:** a similar QRS configuration from beat to beat (Figure 1A). Some variability in QRS morphology at initiation is not uncommon, followed by stabilization of the QRS morphology.
Monomorphic VT with indeterminate QRS morphology*:** preferred over ***ventricular flutter; it is a term that has been applied to rapid VT that has a sinusoidal QRS configuration that prevents identification of the QRS morphology.
***Multiple monomorphic VTs*:** more than one morphologically distinct monomorphic VT, occurring as different episodes or induced at different times.
***Pleomorphic VT*:** has more than one morphologically distinct QRS complex occurring during the same episode of VT, but the QRS is not continuously changing (Figure 1B).
***Polymorphic VT*:** has a continuously changing QRS configuration from beat to beat, indicating a changing ventricular activation sequence (Figure 1C).
***Right bundle branch block (RBBB)- and left bundle branch block (LBBB)-like VT configurations*:** terms used to describe the dominant deflection in V1, with a dominant R wave described as "RBBB-like" and a dominant S wave with a negative final component in V1 described as "LBBB-like" configurations.
***Torsades de pointes*:** a form of polymorphic VT with continually varying QRS complexes that appear to spiral around the baseline of the ECG lead in a sinusoidal pattern. It is associated with QT prolongation.
***Unmappable VT*:** does not allow interrogation of multiple sites to define the activation sequence or perform entrainment mapping; this could be due to hemodynamic intolerance that necessitates immediate VT termination, spontaneous or pacing-induced transition to other morphologies of VT, or repeated termination during mapping.
Ventricular fibrillation (VF): a chaotic rhythm defined on the surface ECG by undulations that are irregular in both timing and morphology, without discrete QRS complexes.

PVC Morphologies

***Monomorphic PVC*:** PVCs felt reasonably to arise from the same focus. Slight changes in QRS morphology due to different exit sites from the same focus can be present.
***Multiple morphologies of PVC*:** PVCs originating from several different focal locations.
***Predominant PVC morphology*:** the one or more monomorphic PVC morphologies occurring most frequently and serving as the target for ablation.

Mechanisms

***Focal VT*:** a point source of earliest ventricular activation with a spread of activation away in all directions from that site. The mechanism can be automaticity, triggered activity, or microreentry.
***Scar-related reentry*:** arrhythmias that have characteristics of reentry that originate from an area of myocardial scar identified from electrogram characteristics or myocardial imaging. Large reentry circuits that can be defined over several centimeters are commonly referred to as "macroreentry."

AV = atrioventricular; ECG = electrocardiogram; ICD = implantable cardioverter defibrillator; LBBB = left bundle branch block; PES = programmed electrical stimulation; PVC = premature ventricular complex; RBBB = right bundle branch block; SHD = structural heart disease; VT = ventricular tachycardia.




Figure 1 Monomorphic (A), pleomorphic (B), and polymorphic (C) VT. Reproduced with permission of the Heart Rhythm Society from Aliot et al. EHRA/HRS expert consensus on catheter ablation of ventricular arrhythmias. Heart Rhythm 2009;6:886–933. VT = ventricular tachycardia.

Table 3 Anatomical terminology

Term	Definition
RV inflow	The part of the right ventricle (RV) containing the tricuspid valve, chordae, and proximal RV.
RV outflow tract (RVOT)	The conus or infundibulum of the RV, derived from the bulbus cordis. It is bounded by the supraventricular crest and the pulmonic valve.
Tricuspid annulus	Area immediately adjacent to the tricuspid valve, including septal, free wall, and para-Hisian regions.
Moderator band	A muscular band in the RV, typically located in the mid to apical RV, connecting the interventricular septum to the RV free wall, supporting the anterior papillary muscle. It typically contains a subdivision of the right bundle branch (RBB).
RV papillary muscles	Three muscles connecting the RV myocardium to the tricuspid valve via the tricuspid chordae tendineae, usually designated as septal, posterior, and anterior papillary muscles. The septal papillary muscle is closely associated with parts of the RBB.
Supraventricular crest	Muscular ridge in the RV between the tricuspid and pulmonic valves, representing the boundary between the conus arteriosus and the rest of the RV. The exact components and terminology are controversial; however, some characterize it as being composed of a parietal band that extends from the anterior RV free wall to meet the septal band, which extends from the septal papillary muscle to meet it.
Pulmonary valves	The pulmonic valve includes three cusps and associated sinus, variously named right, left, and anterior; or anterolateral right, anterolateral left, and posterior sinuses. The posterior-right anterolateral commissure adjoins the aorta (junction of the right and left aortic sinuses). Muscle is present in each of the sinuses, and VA can originate from muscle fibers located within or extending beyond the pulmonary valve apparatus.
Sinuses of Valsalva (SV), aortic cusps, aortic commissures	The right (R), left (L), and noncoronary aortic valve cusps are attached to the respective SV. The left sinus of Valsalva (LSV) is posterior and leftward on the aortic root. The noncoronary sinus of Valsalva (NCSV) is typically the most inferior and posterior SV, located posterior and rightward, superior to the His bundle, and anterior and superior to the paraseptal region of the atria near the superior AV junctions, typically adjacent to atrial myocardium. The right sinus of Valsalva (RSV) is the most anterior cusp and may be posterior to the RVOT infundibulum. VAs can also arise from muscle fibers at the commissures (connections) of the cusps, or from myocardium accessible to mapping and ablation from this location, especially from the RSV/LSV junction.

(*Continued*)

Table 3 (*Continued*)

Term	Definition
LV outflow tract (LVOT)	The aortic vestibule, composed of an infra-valvular part, bounded by the anterior mitral valve leaflet, but otherwise not clearly distinguishable from the rest of the LV; the aortic valve; and a supra-valvular part.
LV ostium	The opening at the base of the LV to which the mitral and aortic valves attach.
Aortomitral continuity (AMC); aortomitral curtain, or mitral-aortic intervalvular fibrosa	Continuation of the anteromedial aspect of the mitral annulus to the aortic valve; a curtain of fibrous tissue extending from the anterior mitral valve leaflet to the left and noncoronary aortic cusps. The AMC is connected by the left and right fibrous trigones to ventricular myocardium, the right fibrous trigone to the membranous ventricular septum.
Mitral valve annulus	Area immediately adjacent to the mitral valve. This can be approached endocardially, or epicardially, either through the coronary venous system or percutaneously.
LV papillary muscles	Muscles connecting the mitral valve chordae tendineae to the LV, typically with posteromedial and anterolateral papillary muscles. Papillary muscle anatomy is variable and can have single or multiple heads.
LV false tendon (or LV moderator band)	A fibrous or fibromuscular chord-like band that crosses the LV cavity, attaching to the septum, papillary muscles, trabeculations, or free wall of the LV. They may contain conduction tissue and may impede catheter manipulation in the LV.
Posterior-superior process	The posterior-superior process of the left ventricle (LV) is the most inferior and posterior aspect of the basal LV, posterior to the plane of the tricuspid valve. VAs originating from the posterior-superior process of the LV can be accessed from the right atrium, the LV endocardium, and the coronary venous system.
Endocardium	Inner lining of the heart.
Purkinje network	The specialized conduction system of the ventricles, which includes the His bundle, RBB and left bundle branches (LBB), and the ramifications of these, found in the subendocardium. The Purkinje system can generate focal or reentrant VTs, typically manifesting Purkinje potentials preceding QRS onset.
Interventricular septum	Muscular wall between the LV and RV.
Membranous ventricular septum	The ventricular septum beneath the RSV and NCSV, through which the penetrating His bundle reaches the ventricular myocardium.
LV summit	Triangular region of the most superior part of the LV epicardial surface bounded by the left circumflex coronary artery, the left anterior descending artery, and an approximate line from the first septal coronary artery laterally to the left AV groove. The great cardiac vein (GCV) bisects the triangle. An area superior to the GCV is considered to be inaccessible to catheter ablation due to proximity of the coronary arteries and overlying epicardial fat.
Crux of the heart (crux cordis)	Epicardial area formed by the junction of the AV groove and posterior interventricular groove, at the base of the heart, approximately at the junction of the middle cardiac vein and coronary sinus (CS) and near the origin of the posterior descending coronary artery.
Epicardium	The outer layer of the heart—the visceral layer of the serous pericardium.
Epicardial fat	Adipose tissue variably present over the epicardial surface around coronary arteries, LV apex, RV free wall, left atrial appendage, right atrial appendage, and AV and interventricular grooves.
Pericardial space or cavity	The potential space between the parietal and visceral layers of serous pericardium, which normally contains a small amount of serous fluid. This space can be accessed for epicardial procedures.
Parietal pericardium	The layer of the serous pericardium that is attached to the inner surface of the fibrous pericardium and is normally apposed to the visceral pericardium, separated by a thin layer of pericardial fluid.
Fibrous pericardium	Thick membrane that forms the outer layer of the pericardium.
Subxiphoid area	Area inferior to the xiphoid process; typical site for percutaneous epicardial access.
Phrenic nerve	The right phrenic nerve lays along the right atrium and does not usually pass over ventricular tissue. The course of the left phrenic nerve on the fibrous pericardium can be quite variable and may run along the lateral margin of the LV near the left obtuse marginal artery and vein; inferior, at the base of the heart; or anterior over the sternocostal surface over the L main stem coronary artery or left anterior descending artery.
Coronary sinus (CS) and branches	The CS and its branches comprise the coronary venous system with the ostium of the CS opening into the right atrium. Tributaries of the CS, which runs along the left AV groove, may be used for mapping. These include the anterior interventricular vein (AIV), which arises at the apex and runs along the anterior interventricular septum, connecting to the GCV that continues in the AV groove to the CS; the communicating vein located between aortic and pulmonary annulus; various posterior and lateral marginal branches or perforator veins; and the middle cardiac vein that typically runs along the posterior interventricular septum from the apex to join the CS or empty separately into the right atrium. The junction of the GCV and the CS is at the vein or ligament of Marshall (or persistent left superior vena cava, when present), and the valve of Vieussens (where present).

Anatomical terminology (S2.1–S2.9). See also Figures 3, 4, 7, and 8. AIV = anterior interventricular vein; AMC = aortomitral continuity; AV = atrioventricular; CS = coronary sinus; GCV = great cardiac vein; LBB = left bundle branch; LSV = left sinus of Valsalva; LV = left ventricle; LVOT = left ventricular outflow tract; NCSV = noncoronary sinus of Valsalva; RBB = right bundle branch; RSV = right sinus of Valsalva; RV = right ventricle; RVOT = right ventricular outflow tract; SV = sinus of Valsalva; VA = ventricular arrhythmia; VT = ventricular tachycardia.

References

S2.1. Yamada T, Kay GN. Anatomical consideration in catheter ablation of idiopathic ventricular arrhythmias. Arrhythm Electrophysiol Rev 2016;5:203–209.

S2.2. Della Bella P, Maccabelli G, Carbucicchio C. Anatomical assessment for catheter ablation of ventricular tachycardia. In: Auricchio A, ed. Cardiac Imaging in Electrophysiology. London: Springer-Verlag; 2012. p. 95–104.

S2.3. Enriquez A, Malavassi F, Saenz LC, Supple G, Santangeli P, Marchlinski FE, Garcia FC. How to map and ablate left ventricular summit arrhythmias. Heart Rhythm 2017;14:141–148.

S2.4. Saremi F, Muresian H, Sanchez-Quintana D. Coronary veins: comprehensive CT-anatomic classification and review of variants and clinical implications. Radiographics 2012;32:E1–E32.

S2.5. Ho SY. Anatomic insights for catheter ablation of ventricular tachycardia. Heart Rhythm 2009;6(Suppl. 8):S77–S80.

S2.6. Ho SY, Nihoyannopoulos P. Anatomy, echocardiography, and normal right ventricular dimensions. Heart 2006;92(Suppl. 1):i2–i13.

S2.7. Sánchez-Quintana D, Ho SY, Climent V, Murillo M, Cabrera JA. Anatomic evaluation of the left phrenic nerve relevant to epicardial and endocardial catheter ablation: implications for phrenic nerve injury. Heart Rhythm 2009;6:764–768.

S2.8. Yamada T, Litovsky SH, Kay GN. The left ventricular ostium: an anatomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythm Electrophysiol 2008;1:396–404.

S2.9. McAlpine WA. Heart and Coronary Arteries: An Anatomical Atlas for Clinical Diagnosis, Radiological Investigation, and Surgical Treatment. New York: Springer-Verlag; 1975.

Section 3 Clinical Evaluation

This section discusses clinical presentations of patients with VAs and their workup as it pertains to documentation of arrhythmias and appropriate testing to assess for the presence of SHD.

3.1. Clinical Presentation

Recommendation for clinical evaluation of patients with VAs

COR	LOE	Recommendation
I	C-EO	**1. A careful clinical evaluation including history, physical examination, review of available cardiac rhythm data, prior imaging, and relevant laboratory workup should be performed in patients presenting with VAs.**

3.2. Diagnostic Evaluation

3.2.1. Resting 12-Lead Electrocardiogram

Recommendations for resting 12-lead ECG

COR	LOE	Recommendations	References
I	B-NR	**1. In patients with wide complex tachycardia, a 12-lead ECG during tachycardia should be obtained whenever possible.**	S3.2.1.1–S3.2.1.15
I	B-NR	**2. In patients with suspected or documented VA, a 12-lead ECG should be obtained in sinus rhythm to look for evidence of underlying heart disease.**	S3.2.1.16

References

S3.2.1.1. Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation 1991;83:1649–1659.

S3.2.1.2. Wellens HJ, Bar FW, Lie KI. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med 1978;64:27–33.

S3.2.1.3. Vereckei A, Duray G, Szenasi G, Altemose GT, Miller JM. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm 2008;5:89–98.

S3.2.1.4. Ohe T, Shimomura K, Aihara N, et al. Idiopathic sustained left ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation 1988;77:560–568.

S3.2.1.5. Dixit S, Gerstenfeld EP, Callans DJ, Marchlinski FE. Electrocardiographic patterns of superior right ventricular outflow tract tachycardias: distinguishing septal and free-wall sites of origin. J Cardiovasc Electrophysiol 2003;14:1–7.

S3.2.1.6. Callans DJ, Menz V, Schwartzman D, Gottlieb CD, Marchlinski FE. Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol 1997;29:1023–1027.

S3.2.1.7. Kanagaratnam L, Tomassoni G, Schweikert R, et al. Ventricular tachycardias arising from the aortic sinus of Valsalva: an under-recognized variant of left outflow tract ventricular tachycardia. J Am Coll Cardiol 2001;37:1408–1414.

S3.2.1.8. Crawford T, Mueller G, Good E, et al. Ventricular arrhythmias originating from papillary muscles in the right ventricle. Heart Rhythm 2010;7:725–730.

S3.2.1.9. Yamada T, McElderry HT, Okada T, et al. Idiopathic focal ventricular arrhythmias originating from the anterior papillary muscle in the left ventricle. J Cardiovasc Electrophysiol 2009;20:866–872.

S3.2.1.10. Li S, Wang Z, Shan Z, et al. Surface electrocardiography characteristics and radiofrequency catheter ablation of idiopathic ventricular arrhythmias originating from the left infero-septal papillary muscles: differences from those originating from the left posterior fascicle. Europace 2018;20:1028–1034.

S3.2.1.11. Berruezo A, Mont L, Nava S, Chueca E, Bartholomay E, Brugada J. Electrocardiographic recognition of the epicardial origin of ventricular tachycardias. Circulation 2004;109:1842–1847.

S3.2.1.12. Daniels DV, Lu YY, Morton JB, et al. Idiopathic epicardial left ventricular tachycardia originating remote from the sinus of Valsalva: electrophysiological characteristics, catheter ablation, and identification from the 12-lead electrocardiogram. Circulation 2006;113:1659–1666.

S3.2.1.13. Bazan V, Gerstenfeld EP, Garcia FC, et al. Site-specific twelve-lead ECG features to identify an epicardial origin for left ventricular tachycardia in the absence of myocardial infarction. Heart Rhythm 2007;4:1403–1410.

S3.2.1.14. Valles E, Bazan V, Marchlinski FE. ECG Criteria to identify epicardial ventricular tachycardia in nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol 2010;3:63–71.

S3.2.1.15. Bazan V, Bala R, Garcia FC, et al. Twelve-lead ECG features to identify ventricular tachycardia arising from the epicardial right ventricle. Heart Rhythm 2006;3:1132–1139.

S3.2.1.16. Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al. Prognostic value of the electrocardiogram in patients with syncope: data from the group for syncope study in the emergency room (GESINUR). Heart Rhythm 2014;11:2035–2044.

3.2.2. Assessment of Structural Heart Disease and Myocardial Ischemia

Recommendations for assessment of SHD and myocardial ischemia

COR	LOE	Recommendations	References
I	B-NR	1. In patients with known or suspected VA, echocardiography is recommended for evaluation of cardiac structure and function.	S3.2.2.1,S3.2.2.2
IIa	B-NR	2. In patients presenting with VA who are suspected of having SHD, even after normal echocardiographic evaluation, advanced cardiac imaging can be useful to detect and characterize underlying SHD.	S3.2.2.3–S3.2.2.7
IIa	C-EO	3. In patients with VA in whom myocardial ischemia is suspected, stress testing and/or coronary angiography and subsequent revascularization can be beneficial before catheter ablation to avoid significant ischemia during induced VT.	
III: No Benefit	B-NR	4. In patients presenting with monomorphic VT, revascularization alone is not effective to prevent VT recurrence.	S3.2.2.8–S3.2.2.10

References

S3.2.2.1. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005;352:2581–2588.

S3.2.2.2. Gula LJ, Klein GJ, Hellkamp AS, et al. Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2008;156:1196–1200.

S3.2.2.3. Yoon Y, Ktagawa K, Kato S, et al. Prognostic value of unrecognised myocardial infarction detected by late gadolinium-enhanced MRI in diabetic patients with normal global and regional left ventricular systolic function. Eur Radiol 2013;23:2101–2108.

S3.2.2.4. Olivotto I, Maron M, Autore C, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008;52:559–566.

S3.2.2.5. Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramural scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ Arrhythm Electrophysiol 2013;6:891–897.

S3.2.2.6. Dweck M, Abgral R, Trivieri M, et al. Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging 2018; 11:94–107.

S3.2.2.7. Piers SR, Tao Q, van Huls van Taxis CF, Schalij MJ, van der Geest RJ, Zeppenfeld K. Contrast-enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonischemic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol 2013; 6:875–883.

S3.2.2.8. Brugada J, Aguinaga L, Mont L, Betriu A, Mulet J, Sanz G. Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. J Am Coll Cardiol 2001; 37:529–533.

S3.2.2.9. Nageh M, Kim J, Chen L, Yao JF. Implantable defibrillators for secondary prevention of sudden cardiac death in cardiac surgery patients with perioperative ventricular arrhythmias. J Am Heart Assoc 2014; 3:e000686.

S3.2.2.10. Elsokkari I, Parkash R, Gray C, et al. Effect of coronary revascularization on long-term clinical outcomes in patients with ischemic cardiomyopathy and recurrent ventricular arrhythmia. Pacing Clin Electrophysiol 2018;41:775–779.

3.2.3. Risk Stratification in the Setting of Frequent Premature Ventricular Complexes

Recommendations for cardiac magnetic resonance imaging (CMR) in patients with frequent PVCs and for PES in patients with SHD and frequent PVCs

COR	LOE	Recommendations	References
IIa	B-NR	1. CMR can be useful for risk stratification for sudden cardiac death in patients with frequent PVCs.	S3.2.3.1,S3.2.3.2
IIa	C-LD	2. PES can be useful for risk stratification for sudden cardiac death in patients with SHD undergoing ablation of frequent PVCs.	S3.2.3.2

References

S3.2.3.1. Aquaro GD, Pingitore A, Strata E, Di Bella G, Molinaro S, Lombardi M. Cardiac magnetic resonance predicts outcome in patients with premature ventricular complexes of left bundle branch block morphology. J Am Coll Cardiol 2010;56:1235–1243.

S3.2.3.2. Yokokawa M, Siontis KC, Kim HM, et al. Value of cardiac magnetic resonance imaging and programmed ventricular stimulation in patients with frequent premature ventricular complexes undergoing radiofrequency ablation. Heart Rhythm 2017;14:1695–1701.

3.2.4. Longitudinal Follow-up in the Setting of Frequent Premature Ventricular Complexes

Recommendation for longitudinal follow-up of patients with frequent PVCs			
COR	LOE	Recommendation	Reference
IIa	B-NR	**1. Periodic monitoring of PVC burden and LV function and dimensions can be useful in patients with frequent, asymptomatic PVCs and normal LV function and dimensions.**	S3.2.4.1

Reference

S3.2.4.1. Niwano SY, Wakisaka H, Niwano H, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart 2009;95:1230–1237.

Section 4 Indications for Catheter Ablation

Following are the consensus recommendations for catheter ablation of VAs organized by underlying diagnosis and substrate. These recommendations are each assigned a COR and an LOE according to the current recommendation classification system (S4.1). In drafting each of these recommendations, the writing committee took into account the published literature in the specific area, including the methodological quality and size of each study, as well as the collective clinical experience of the writing group when published data were not available. Implicit in each recommendation are several points: 1) the procedure is being performed by an electrophysiologist with appropriate training and experience in the procedure and in a facility with appropriate resources; 2) patient and procedural complexity vary widely, and some patients or situations merit a more experienced operator or a center with more capabilities than others, even within the same recommendation (eg, when an epicardial procedure is indicated and the operator or institution has limited experience with this procedure, it might be preferable to refer the patient to an operator or institution with adequate experience in performing epicardial procedures); 3) the patient is an appropriate candidate for the procedure, as outlined in Section 5, recognizing that the level of patient suitability for a procedure will vary widely with the clinical scenario; and 4) the patient's (or designee's) informed consent, values, and overall clinical trajectory are fundamental to a decision to proceed (or not) with any procedure. Therefore, in some clinical scenarios, initiation or continuation of medical therapy instead of an ablation procedure may be the most appropriate option, even when a class 1 recommendation for ablation is present. There may also be scenarios not explicitly covered in this document, and on which little or no published literature is available, in which the physician and patient must rely solely on their own judgment.

Figure 2 provides an overview of care for the patient with congenital heart disease (CHD) and VA.

Reference

S4.1. Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2006;133:1426–1428.

4.1. Idiopathic Outflow Tract Ventricular Arrhythmia

Recommendations for catheter ablation of idiopathic outflow tract VA			
COR	LOE	Recommendations	References
I	B-R	**1. In patients with frequent and symptomatic PVCs originating from the RVOT in an otherwise normal heart, catheter ablation is recommended in preference to metoprolol or propafenone.**	S4.1.1
I	B-NR	**2. In patients with symptomatic VAs from the RVOT in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation is useful.**	S4.1.2–S4.1.12
I	B-NR	**3. In patients with symptomatic idiopathic sustained monomorphic VT, catheter ablation is useful.**	S4.1.13–S4.1.17
IIa	B-NR	**4. In patients with symptomatic VAs from the endocardial LVOT, including the SV, in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation can be useful.**	S4.1.18–S4.1.27
IIa	B-NR	**5. In patients with symptomatic VAs from the epicardial outflow tract or LV summit in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation can be useful.**	S4.1.28–S4.1.32

References

S4.1.1. Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract: prospective randomized study. Circ Arrhythm Electrophysiol 2014;7:237–243.

S4.1.2. Zhang F, Yang B, Chen H, Ju W, Kojodjojo P, Cao K, Chen M. Magnetic versus manual catheter navigation for mapping and ablation of right ventricular outflow tract ventricular arrhythmias: a randomized controlled study. Heart Rhythm 2013;10:1178–1183.

S4.1.3. Krittayaphong R, Sriratanasathavorn C, Dumavibhat C, et al. Electrocardiographic predictors of long term outcomes after radiofrequency ablation in patients with right-ventricular outflow tract tachycardia. Europace 2006;8:601–606.

S4.1.4. Vestal M, Wen MS, Yeh SJ, Wang CC, Lin FC, Wu D. Electrocardiographic predictors of failure and recurrence in patients with idiopathic right

ventricular outflow tract tachycardia and ectopy who underwent radiofrequency catheter ablation. J Electrocardiol 2003;36:327–332.
S4.1.5. Miyazawa K, Ueda M, Kondo Y, Hayashi T, Nakano M, Ishimura M, Nakano M, Kobayashi Y. Rapid mapping and differentiation in ventricular outflow tract arrhythmia using non-contact mapping. J Interv Card Electrophysiol 2017;49:41–49.
S4.1.6. Akdeniz C, Gul EE, Celik N, Karacan M, Tuzcu V. Catheter ablation of idiopathic right ventricular arrhythmias in children with limited fluoroscopy. J Interv Card Electrophysiol 2016;46:355–360.
S4.1.7. Morady F, Kadish AH, DiCarlo L, Kou WH, Winston S, deBuitlier M, Calkins H, Rosenheck S, Sousa J. Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation 1990;82:2093–2099.
S4.1.8. Liao Z, Zhan X, Wu S, et al. Idiopathic ventricular arrhythmias originating from the pulmonary sinus cusp: prevalence, electrocardiographic/electrophysiological characteristics, and catheter ablation. J Am Coll Cardiol 2015;66:2633–2644.
S4.1.9. Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E, Jongnarangsin K, Marine JE, Chugh A, Pelosi F, Oral H, Morady F. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007;4:863–867.
S4.1.10. Chen H, Shehata M, Swerdlow C, et al. Intramural outflow tract ventricular tachycardia: anatomy, mapping, and ablation. Circ Arrhythm Electrophysiol 2014;7:978–981.
S4.1.11. Teh AW, Reddy VY, Koruth JS, et al. Bipolar radiofrequency catheter ablation for refractory ventricular outflow tract arrhythmias. J Cardiovasc Electrophysiol 2014;25:1093–1099.
S4.1.12. Lamba J, Redfearn DP, Michael KA, Simpson CS, Abdollah H, Baranchuk A. Radiofrequency catheter ablation for the treatment of idiopathic premature ventricular contractions originating from the right ventricular outflow tract: a systematic review and meta-analysis. Pacing Clin Electrophysiol 2014;37:73–78.
S4.1.13. Calkins H, Kalbfleisch J, El-Atassi R, Langberg J, Morady F. Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. Am J Cardiol 1993;71:827–833.
S4.1.14. Rodriguez LM, Smeets JL, Timmermans C, Wellens HJ. Predictors for successful ablation of right- and left-sided idiopathic ventricular tachycardia. Am J Cardiol 1997;79:309–314.
S4.1.15. Coggins DL, Lee RJ, Sweeney J, et al. Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. J Am Coll Cardiol 1994;23:1333–1341.
S4.1.16. Wen MS, Yeh SJ, Wang CC, Lin FC, Chen IC, Wu D. Radiofrequency ablation therapy in idiopathic left ventricular tachycardia with no obvious structural heart disease. Circulation 1994;89:1690–1696.
S4.1.17. Movsowitz C, Schwartzman D, Callans DJ, et al. Idiopathic right ventricular outflow tract tachycardia: narrowing the anatomic location for successful ablation. Am Heart J 1996;131:930–936.
S4.1.18. Frey B, Kreiner G, Fritsch S, Veit F, Gossinger HD. Successful treatment of idiopathic left ventricular outflow tract tachycardia by catheter ablation or minimally invasive surgical cryoablation. Pacing Clin Electrophysiol 2000;23:870–876.
S4.1.19. Krebs ME, Krause PC, Engelstein ED, Zipes DP, Miles WM. Ventricular tachycardias mimicking those arising from the right ventricular outflow tract. J Cardiovasc Electrophysiol 2000;11:45–51.
S4.1.20. Kumagai K, Fukuda K, Wakayama Y, et al. Electrocardiographic characteristics of the variants of idiopathic left ventricular outflow tract ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 2008;19:495–501.
S4.1.21. Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol 2015;1:116–123.
S4.1.22. Kamakura S, Shimizu W, Matsuo K, et al. Localization of optimal ablation site of idiopathic ventricular tachycardia from right and left ventricular outflow tract by body surface ECG. Circulation 1998;98:1525–1533.
S4.1.23. Yamada T, Yoshida N, Murakami Y, et al. Electrocardiographic characteristics of ventricular arrhythmias originating from the junction of the left and right coronary sinuses of Valsalva in the aorta: the activation pattern as a rationale for the electrocardiographic characteristics. Heart Rhythm 2008;5:184–192.
S4.1.24. Tada H, Naito S, Ito S, et al. Significance of two potentials for predicting successful catheter ablation from the left sinus of Valsalva for left ventricular epicardial tachycardia. Pacing Clin Electrophysiol 2004;27:1053–1059.
S4.1.25. Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol 2002;39:500–508.
S4.1.26. Callans DJ, Menz V, Schwartzman D, Gottlieb CD, Marchlinski FE. Repetitive monomorphic tachycardia from the left ventricular outflow tract: electrocardiographic patterns consistent with a left ventricular site of origin. J Am Coll Cardiol 1997;29:1023–1027.
S4.1.27. Bala R, Garcia FC, Hutchinson MD, et al. Electrocardiographic and electrophysiologic features of ventricular arrhythmias originating from the right/left coronary cusp commissure. Heart Rhythm 2010;7:312–322.
S4.1.28. Tada H, Nogami A, Naito S, et al. Left ventricular epicardial outflow tract tachycardia: a new distinct subgroup of outflow tract tachycardia. Jpn Circ J 2001;65:723–730.
S4.1.29. Baman TS, Ilg KJ, Gupta SK, et al. Mapping and ablation of epicardial idiopathic ventricular arrhythmias from within the coronary venous system. Circ Arrhythm Electrophysiol 2010;3:274–279.
S4.1.30. Carrigan T, Patel S, Yokokawa M, Schmidlin E, Swanson S, Morady F, Bogun F. Anatomic relationships between the coronary venous system, surrounding structures, and the site of origin of epicardial ventricular arrhythmias. J Cardiovasc Electrophysiol 2014;25:1336–1342.
S4.1.31. Santangeli P, Marchlinski FE, Zado ES, et al. Percutaneous epicardial ablation of ventricular arrhythmias arising from the left ventricular summit: outcomes and electrocardiogram correlates of success. Circ Arrhythm Electrophysiol 2015;8:337–343.
S4.1.32. Nagashima K, Choi EK, Lin KY, et al. Ventricular arrhythmias near the distal great cardiac vein: challenging arrhythmia for ablation. Circ Arrhythm Electrophysiol 2014;7:906–912.

4.2. Idiopathic Nonoutflow Tract Ventricular Arrhythmia

Recommendations for catheter ablation of nonoutflow tract VAs in the absence of SHD

COR	LOE	Recommendations	References
I	B-NR	**1. In patients with symptomatic VAs from the RV at sites other than the outflow tracts (tricuspid annulus, moderator band, parietal band, or papillary muscles) in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation is useful.**	S4.2.1–S4.2.14
I	B-NR	**2. In patients with symptomatic VAs from the LV at sites other than the outflow tracts (mitral annulus, papillary muscles, or AMC) in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation is useful.**	S4.2.15–S4.2.31
IIa	B-NR	**3. In patients with symptomatic VAs from the epicardial coronary venous system in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation can be useful.**	S4.2.32–S4.2.43
IIa	B-NR	**4. In patients with symptomatic VAs from para-Hisian sites in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation can be useful.**	S4.2.7,S4.2.13, S4.2.14,S4.2.44–S4.2.49
IIa	C-LD	**5. In patients with symptomatic VAs from the posterior-superior process of the LV in an otherwise normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference, catheter ablation from the LV endocardium, right atrium, or CS, can be useful.**	S4.2.50–S4.2.52

References

S4.2.1. Van Herendael H, Garcia F, Lin D, et al. Idiopathic right ventricular arrhythmias not arising from the outflow tract: prevalence, electrocardiographic characteristics, and outcome of catheter ablation. Heart Rhythm 2011; 8:511–518.

S4.2.2. Sadek MM, Benhayon D, Sureddi R, et al. Idiopathic ventricular arrhythmias originating from the moderator band: electrocardiographic characteristics and treatment by catheter ablation. Heart Rhythm 2015;12:67–75.

S4.2.3. Crawford T, Mueller G, Good E, et al. Ventricular arrhythmias originating from papillary muscles in the right ventricle. Heart Rhythm 2010; 7:725–730.

S4.2.4. Tada H, Tadokoro K, Miyaji K, et al. Idiopathic ventricular arrhythmias arising from the pulmonary artery: prevalence, characteristics, and topography of the arrhythmia origin. Heart Rhythm 2008;5:419–426.

S4.2.5. Tada H, Tadokoro K, Ito S, et al. Idiopathic ventricular arrhythmias originating from the tricuspid annulus: prevalence, electrocardiographic characteristics, and results of radiofrequency catheter ablation. Heart Rhythm 2007;4:7–16.

S4.2.6. Santoro F, DiBiase L, Hranitzky P, et al. Ventricular tachycardia originating from the septal papillary muscle of the right ventricle: electrocardiographic and electrophysiological characteristics. J Cardiovasc Electrophysiol 2015; 26:145–150.

S4.2.7. Sasaki K, Sasaki S, Kimura M, et al. Catheter ablation of ventricular arrhythmias arising from the basal septum of the right ventricle: characteristics and significance of junctional rhythm appearing during ablation. J Interv Card Electrophysiol 2016;45:159–167.

S4.2.8. Yue-Chun L, Wen-Wu Z, Na-Dan Z, et al. Idiopathic premature ventricular contractions and ventricular tachycardias originating from the vicinity of tricuspid annulus: results of radiofrequency catheter ablation in thirty-five patients. BMC Cardiovasc Disord 2012;10:12–32.

S4.2.9. Yamada T, Yoshida N, Itoh T, Litovsky SH, Doppalapudi H, McElderry HT, Kay GN. Idiopathic ventricular arrhythmias originating from the parietal band: electrocardiographic and electrophysiological characteristics and outcome of catheter ablation. Circ Arrhythm Electrophysiol 2017;10:e005099.

S4.2.10. Ceresnak SR, Pass RH, Krumerman AK, Kim SG, Nappo L, Fisher JD. Characteristics of ventricular tachycardia arising from the inflow region of the right ventricle. J Electrocardiol 2012;45:385–390.

S4.2.11. Yamada T, Yoshida N, Litovsky SH, Itoh T, Doppalapudi H, Kay GN. Idiopathic ventricular arrhythmias originating from the infundibular muscles: prevalence, electrocardiographic and electrophysiological characteristics, and outcome of catheter ablation. Circ Arrhythm Electrophysiol 2018; 11:e005749.

S4.2.12. Li T, Zhan XZ, Xue YM, et al. Combined approach improves the outcomes of catheter ablation of idiopathic ventricular arrhythmias originating from the vicinity of tricuspid annulus. Pacing Clin Electrophysiol 2014; 37:624–629.

S4.2.13. Lian-Pin W, Yue-Chun L, Jing-Lin Z, et al. Catheter ablation of idiopathic premature ventricular contractions and ventricular tachycardias originating from right ventricular septum. PLoS One 2013;8:e67038.

S4.2.14. Enriquez A, Pathak RK, Santangeli P, et al. Inferior lead discordance in ventricular arrhythmias: a specific marker for certain arrhythmia locations. J Cardiovasc Electrophysiol 2017;28:1179–1186.

S4.2.15. Doppalapudi H, Yamada T, McElderry HT, Plumb VJ, Epstein AE, Kay GN. Ventricular tachycardia originating from the posterior papillary muscle in the left ventricle: a distinct clinical syndrome. Circ Arrhythm Electrophysiol 2008;1:23–29.

S4.2.16. Yamada T, McElderry HT, Okada T, et al. Idiopathic focal ventricular arrhythmias originating from the anterior papillary muscle in the left ventricle. J Cardiovasc Electrophysiol 2009;20:866–872.

S4.2.17. Yamada T, Doppalapudi H, McElderry HT, et al. Idiopathic ventricular arrhythmias originating from the papillary muscles in the left ventricle: prevalence, electrocardiographic and electrophysiological characteristics, and results of the radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2010;21:62–69.

S4.2.18. Yamada T, Doppalapudi H, McElderry HT, et al. Electrocardiographic and electrophysiological characteristics in idiopathic ventricular arrhythmias originating from the papillary muscles in the left ventricle: relevance for catheter ablation. Circ Arrhythm Electrophysiol 2010;3:324–331.

S4.2.19. Bassil G, Liu CF, Markowitz SM, et al. Comparison of robotic magnetic navigation-guided and manual catheter ablation of ventricular arrhythmias arising from the papillary muscles. Europace 2018;20(Suppl. 2):ii5–ii10.

S4.2.20. Ban JE, Lee HS, Lee DI, et al. Electrophysiological characteristics related to outcome after catheter ablation of idiopathic ventricular arrhythmia originating from the papillary muscle in the left ventricle. Korean Circ J 2013; 43:811–818.

S4.2.21. Yokokawa M, Good E, Desjardins B, et al. Predictors of successful catheter ablation of ventricular arrhythmias arising from the papillary muscles. Heart Rhythm 2010;7:1654–1659.

S4.2.22. Rivera S, Ricapito Mde L, Tomas L, et al. Results of cryoenergy and radiofrequency-based catheter ablation for treating ventricular arrhythmias arising from the papillary muscles of the left ventricle, guided by intracardiac echocardiography and image integration. Circ Arrhythm Electrophysiol 2016;9:e003874.

S4.2.23. Al'Aref SJ, Ip JE, Markowitz SM, et al. Differentiation of papillary muscle from fascicular and mitral annular ventricular arrhythmias in patients with and without structural heart disease. Circ Arrhythm Electrophysiol 2015; 8:616–624.

S4.2.24. Wasmer K, Köbe J, Dechering DG, et al. Ventricular arrhythmias from the mitral annulus: patient characteristics, electrophysiological findings, ablation, and prognosis. Heart Rhythm 2013;10:783–788.

S4.2.25. Kumagai K, Yamauchi Y, Takahashi A, et al. Idiopathic left ventricular tachycardia originating from the mitral annulus. J Cardiovasc Electrophysiol 2005;16:1029–1036.

S4.2.26. Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ventricular arrhythmias. J Am Coll Cardiol 2005;45:877–886.

S4.2.27. Yue-Chun L, Cheng Z, Jun H, Jun-Hua C, Jing-Lin Z, Jia-Feng L. Catheter ablation of idiopathic premature ventricular contractions and ventricular tachycardias originating from the vicinity of endocardial and epicardial mitral annulus. PLoS One 2013;8:e80777.

S4.2.28. Yamada T, Doppalapudi H, McElderry HT, Kay GN. Idiopathic mitral annular PVCs with multiple breakouts and preferential conduction unmasked by radiofrequency catheter ablation. Pacing Clin Electrophysiol 2012;35:e112–e115.

S4.2.29. Yamada T, Litovsky SH, Kay GN. The left ventricular ostium: an anatomic concept relevant to idiopathic ventricular arrhythmias. Circ Arrhythmia Electrophysiol 2008;1:396–404.

S4.2.30. Chen J, Hoff PI, Rossvoll O, et al. Ventricular arrhythmias originating from the aortomitral continuity: an uncommon variant of left ventricular outflow tract tachycardia. Europace 2012;14:388–395.

S4.2.31. Hai JJ, Chahal AA, Friedman PA, et al. Electrophysiologic characteristics of ventricular arrhythmias arising from the aortic mitral continuity-potential role of the conduction system. J Cardiovasc Electrophysiol 2015;26:158–163.

S4.2.32. Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricular arrhythmias originating from the left ventricular summit: anatomic concepts relevant to ablation. Circ Arrhythm Electrophysiol 2010;3:616–623.

S4.2.33. Baman TS, Ilg KJ, Gupta SK, et al. Mapping and ablation of epicardial idiopathic ventricular arrhythmias from within the coronary venous system. Circ Arrhythm Electrophysiol 2010;3:274–279.

S4.2.34. Mountantonakis SE, Frankel DS, Tschabrunn CM, et al. Ventricular arrhythmias from the coronary venous system: prevalence, mapping, and ablation. Heart Rhythm 2015;12:1145–1153.

S4.2.35. Meininger GR, Berger RD. Idiopathic ventricular tachycardia originating in the great cardiac vein. Heart Rhythm 2006;3:464–466.

S4.2.36. Yamada T, Doppalapudi H, Litovsky SH, McElderry HT, Kay GN. Challenging radiofrequency catheter ablation of idiopathic ventricular arrhythmias originating from the left ventricular summit near the left main coronary artery. Circ Arrhythm Electrophysiol 2016;9:e004202.

S4.2.37. Yokokawa M, Latchamsetty R, Good E, et al. Ablation of epicardial ventricular arrhythmias from nonepicardial sites. Heart Rhythm 2011; 8:1525–1529.

S4.2.38. Jauregui Abularach ME, Campos B, Park KM, et al. Ablation of ventricular arrhythmias arising near the anterior epicardial veins from the left sinus of Valsalva region: ECG features, anatomic distance, and outcome. Heart Rhythm 2012;9:865–873.

S4.2.39. Yokokawa M, Good E, Chugh A, et al. Intramural idiopathic ventricular arrhythmias originating in the intraventricular septum: mapping and ablation. Circ Arrhythm Electrophysiol 2012;5:258–263.

S4.2.40. Doppalapudi H, Yamada T, Ramaswamy K, Ahn J, Kay GN. Idiopathic focal epicardial ventricular tachycardia originating from the crux of the heart. Heart Rhythm 2009;6:44–50.

S4.2.41. Kawamura M, Gerstenfeld EP, Vedantham V, et al. Idiopathic ventricular arrhythmia originating from the cardiac crux or inferior septum. Circ Arrhythm Electrophysiol 2014;7:1152–1158.

S4.2.42. Larroussi L, Badhwar N. Ventricular tachycardia arising from cardiac crux: electrocardiogram recognition and site of ablation. Card Electrophysiol Clin 2016;8:109–113.

S4.2.43. Yui Y, Sekiguchi Y, Nogami A, et al. Electrophysiological characteristics and radiofrequency catheter ablation treatment of idiopathic ventricular

arrhythmias successfully ablated from the ostium of the coronary sinus. Circ J 2017;81:1807–1815.
S4.2.44. Komatsu Y, Otomo K, Taniguchi H, et al. Catheter ablation of ventricular arrhythmias arising from the right ventricular septum close to the His bundle: features of the local electrogram at the optimal ablation site. J Cardiovasc Electrophysiol 2011;22:878–885.
S4.2.45. Yamada T, Plumb VJ, McElderry HT, Doppalapudi H, Epstein AE, Kay GN. Focal ventricular arrhythmias originating from the left ventricle adjacent to the membranous septum. Europace 2010;12:1467–1474.
S4.2.46. Wei HQ, Guo XG, Liu X, et al. Safety and efficacy of catheter ablation of ventricular arrhythmias with para-Hisian origin via a systematic direct approach from the aortic sinus cusp. Heart Rhythm 2018; 15:1626–1633.
S4.2.47. Yamauchi Y, Aonuma K, Takahashi A, et al. Electrocardiographic characteristics of repetitive monomorphic right ventricular tachycardia originating near the His-bundle. J Cardiovasc Electrophysiol 2005;16:1041–1048.
S4.2.48. Komatsu Y, Taniguchi H, Miyazaki S, et al. Two distinct electrocardiographic forms of idiopathic ventricular arrhythmia originating in the vicinity of the His bundle. Europace 2012;14:1778–1785.
S4.2.49. Enriquez A, Tapias C, Rodriguez D, et al. How to map and ablate parahisian ventricular arrhythmias. Heart Rhythm 2018;15:1268–1274.
S4.2.50. Santangeli P, Hutchinson MD, Supple GE, Callans DJ, Marchlinski FE, Garcia FC. Right atrial approach for ablation of ventricular arrhythmias arising from the left posterior-superior process of the left ventricle. Circ Arrhythm Electrophysiol 2016;9:e004048.
S4.2.51. Li A, Zuberi Z, Bradfield JS, et al. Endocardial ablation of ventricular ectopic beats arising from the basal inferoseptal process of the left ventricle. Heart Rhythm 2018;15:1356–1362.
S4.2.52. Tavares L, Dave A, Valderrábano M. Successful ablation of premature ventricular contractions originating from the inferoseptal process of the left ventricle using a coronary sinus approach. HeartRhythm Case Rep 2018; 4:371–374.

4.3. Premature Ventricular Complexes With or Without Left Ventricular Dysfunction

Recommendations for catheter ablation of PVCs in patients with or without LV dysfunction

COR	LOE	Recommendations	References
I	B-NR	**1. In patients with cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs and for whom AADs are ineffective, not tolerated, or not preferred for long-term therapy, catheter ablation is recommended.**	S4.3.1–S4.3.10
IIa	B-NR	**2. In patients with SHD in whom frequent PVCs are suspected to be contributing to a cardiomyopathy and for whom AADs are ineffective, not tolerated, or not preferred for long-term therapy, catheter ablation can be useful.**	S4.3.3,S4.3.11,S4.3.12
IIa	B-NR	**3. In patients with focally triggered VF refractory to AADs and triggered by a similar PVC, catheter ablation can be useful.**	S4.3.13–S4.3.17
IIa	C-LD	**4. In nonresponders to cardiac resynchronization therapy with very frequent unifocal PVCs limiting optimal biventricular pacing despite pharmacological therapy, catheter ablation can be useful.**	S4.3.18

References

S4.3.1. Latchamsetty RY, Morady M, Kim F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clinical Electrophysiol 2015;1:116–123.
S4.3.2. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995;333:77–82.
S4.3.3. Mountantonakis SE, Frankel DS, Gerstenfeld EP, et al. Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm 2011;8:1608–1614.
S4.3.4. Zang M, Zhang T, Mao J, Zhou S, He B. Beneficial effects of catheter ablation of frequent premature ventricular complexes on left ventricular function. Heart 2014;100:787–793.
S4.3.5. Lee A, Denman R, Haqqani HM. Ventricular ectopy in the context of left ventricular systolic dysfunction: risk factors and outcomes following catheter ablation. Heart Lung Circ 2019;28:379–388.
S4.3.6. Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007;4:863–867.
S4.3.7. Takemoto M, Yoshimura H, Ohba Y, et al. Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease. J Am Coll Cardiol 2005;45:1259–1265.
S4.3.8. Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010;7:865–869.
S4.3.9. Yarlagadda RK, Iwai S, Stein KM, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005;112:1092–1097.
S4.3.10. Wijnmaalen AP, Delgado V, Schalij MJ, et al. Beneficial effects of catheter ablation on left ventricular and right ventricular function in patients with frequent premature ventricular contractions and preserved ejection fraction. Heart 2010;96:1275–1280.
S4.3.11. Sarrazin JF, Labounty T, Kuhne M, et al. Impact of radiofrequency ablation of frequent post-infarction premature ventricular complexes on left ventricular ejection fraction. Heart Rhythm 2009;6:1543–1549.
S4.3.12. El Kadri M, Yokokawa M, Labounty T, et al. Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. Heart Rhythm 2015;12:706–713.
S4.3.13. Haïssaguerre M, Shoda M, Jaïs P, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation 2002;106:962–967.
S4.3.14. Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. J Am Coll Cardiol 2009; 54:522–528.
S4.3.15. Peichl P, Cihák R, Kozeluhová M, Wichterle D, Vancura V, Kautzner J. Catheter ablation of arrhythmic storm triggered by monomorphic ectopic beats in patients with coronary artery disease. J Interv Card Electrophysiol 2010;27:51–59.
S4.3.16. Haïssaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003;108:925–928.
S4.3.17. Sadek MM, Benhayon D, Sureddi R, et al. Idiopathic ventricular arrhythmias originating from the moderator band: electrocardiographic characteristics and treatment by catheter ablation. Heart Rhythm 2015; 12:67–75.
S4.3.18. Lakkireddy D, Di Biase L, Ryschon K, et al. Radiofrequency ablation of premature ventricular ectopy improves the efficacy of cardiac resynchronization therapy in nonresponders. J Am Coll Cardiol 2012; 60:1531–1539.

4.4. Ventricular Arrhythmia in Ischemic Heart Disease

Recommendations for catheter ablation of VAs in patients with IHD

COR	LOE	Recommendations	References
I	B-R	1. In patients with IHD who experience recurrent monomorphic VT despite chronic amiodarone therapy, catheter ablation is recommended in preference to escalating AAD therapy.	S4.4.1
I	B-NR	2. In patients with IHD and recurrent symptomatic monomorphic VT despite AAD therapy, or when AAD therapy is contraindicated or not tolerated, catheter ablation is recommended to reduce recurrent VT.	S4.4.2–S4.4.4
I	B-NR	3. In patients with IHD and VT storm refractory to AAD therapy, catheter ablation is recommended.	S4.4.5–S4.4.9
IIa	C-EO	4. In patients with IHD and recurrent monomorphic VT, in whom AADs are not desired, catheter ablation can be useful.	
IIb	A	5. In patients with IHD and an ICD who experience a first episode of monomorphic VT, catheter ablation may be considered to reduce the risk of recurrent VT or ICD therapies.	S4.4.10–S4.4.14
IIb	C-LD	6. In patients with prior myocardial infarction and recurrent episodes of symptomatic sustained VT for whom prior endocardial catheter ablation has not been successful and who have ECG, endocardial mapping, or imaging evidence of a subepicardial VT substrate, epicardial ablation may be considered.	S4.4.15–S4.4.19

References

S4.4.1. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;375:111–121.

S4.4.2. Stevenson WG, Wilber DJ, Natale A, et al; Multicenter Thermocool VT Ablation Trial Investigators Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008;118:2773–2782.

S4.4.3. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol 2010;21:47–53.

S4.4.4. Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol 2016;67:674–683.

S4.4.5. Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008;117:462–469.

S4.4.6. Deneke T, Shin D, Lawo T, et al. Catheter ablation of electrical storm in a collaborative hospital network. Am J Cardiol 2011;108:233–239.

S4.4.7. Muser D, Liang JJ, Pathak RK, et al. Long-term outcomes of catheter ablation of electrical storm in nonischemic dilated cardiomyopathy compared with ischemic cardiomyopathy. JACC Clin Electrophysiol 2017;3:767–778.

S4.4.8. Kumar S, Fujii A, Kapur S, et al. Beyond the storm: comparison of clinical factors, arrhythmogenic substrate, and catheter ablation outcomes in structural heart disease patients with versus those without a history of ventricular tachycardia storm. J Cardiovasc Electrophysiol 2017;28:56–67.

S4.4.9. Nayyar S, Ganesan AN, Brooks AG, Sullivan T, Roberts-Thomson KC, Sanders P. Venturing into ventricular arrhythmia storm: a systematic review and meta-analysis. Eur Heart J 2013;34:560–569.

S4.4.10. Reddy VY, Reynolds MR, Neuzil P, et al; Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357:2657–2665.

S4.4.11. Kuck KH, Schaumann A, Eckhardt L, et al; for the VTACH Study Group Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31–40.

S4.4.12. Al-Khatib SM, Daubert JP, Anstrom KJ, et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol 2015;26:151–157.

S4.4.13. Kuck KH, Tilz RR, Deneke T, et al; SMS Investigators. Impact of substrate modification by catheter ablation on implantable cardioverter–defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol 2017;10:e004422.

S4.4.14. Martinez BK, Baker WL, Konopka A, et al. Systematic review and meta-analysis of catheter ablation of ventricular tachycardia in ischemic heart disease. Heart Rhythm 2019 May 10 [Epub ahead of print].

S4.4.15. Littmann L, Svenson RH, Gallagher JJ, et al. Functional role of the epicardium in postinfarction ventricular tachycardia: observations derived from computerized epicardial activation mapping, entrainment, and epicardial laser photoablation. Circulation 1991;83:1577–1591.

S4.4.16. Sosa E, Scanavacca M, d'Avila A, Oliveira F, Ramires JA. Nonsurgical transthoracic epicardial catheter ablation to treat recurrent ventricular tachycardia occurring late after myocardial infarction. J Am Coll Cardiol 2000;35:1442–1449.

S4.4.17. Schmidt B, Chun KR, Baensch D, Antz M, Koektuerk B, Tilz RR, Metzner A, Ouyang F, Kuck KH. Catheter ablation for ventricular tachycardia after failed endocardial ablation: epicardial substrate or inappropriate endocardial ablation? Heart Rhythm 2010;7:1746–1752.

S4.4.18. Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization of the scar versus limited endocardial substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol 2012;60:132–141.

S4.4.19. Izquierdo M, Sánchez-Gómez JM, Ferrero de Loma-Osorio A, Martínez A, Bellver A, Peláez A, Núñez J, Núñez C, Chorro J, Ruiz-Granell R. Endo-epicardial versus only-endocardial ablation as a first line strategy for the treatment of ventricular tachycardia in patients with ischemic heart disease. Circ Arrhythm Electrophysiol 2015;8:882–889.

4.5. Nonischemic Cardiomyopathy

Recommendations for catheter ablation of VT in nonischemic cardiomyopathy (NICM)

COR	LOE	Recommendations	References
I	B-NR	1. In patients with NICM and recurrent sustained monomorphic VT for whom antiarrhythmic medications are ineffective, contraindicated, or not tolerated, catheter ablation is useful for reducing recurrent VT and ICD shocks.	S4.5.1–S4.5.6
I	B-NR	2. In patients with NICM and electrical storm refractory to AAD therapy, catheter ablation is useful for reducing recurrent VT and ICD shocks.	S4.5.7–S4.5.9
IIa	B-NR	3. In patients with NICM, epicardial catheter ablation of VT can be useful after failure of endocardial ablation or as the initial ablation approach when there is a suspicion of an epicardial substrate or circuit.	S4.5.4,S4.5.10–S4.5.13
IIa	B-NR	4. In patients with cardiac sarcoidosis and recurrent VT despite medical therapy, catheter ablation can be useful to reduce the risk of VT recurrence and ICD shocks.	S4.5.14–S4.5.18
IIa	C-EO	5. In patients with NICM and recurrent sustained monomorphic VT for whom antiarrhythmic medications are not desired, catheter ablation can be useful for reducing recurrent VT and ICD shocks.	
IIb	B-NR	6. In patients with NICM related to lamin A/C (*LMNA*) mutations and recurrent VT, catheter ablation may be considered as a palliative strategy for short-term arrhythmia control.	S4.5.19

References

S4.5.1. Muser D, Santangeli P, Castro SA, et al. Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy. Circ Arrhythm Electrophysiol 2016;9:e004328.

S4.5.2. Proietti R, Essebag V, Beardsall J, et al. Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace 2015;17:461–467.

S4.5.3. Dinov B, Arya A, Bertagnolli L, et al. Early referral for ablation of scar-related ventricular tachycardia is associated with improved acute and long-term outcomes: results from the Heart Center of Leipzig ventricular tachycardia registry. Circ Arrhythm Electrophysiol 2014;7:1144–1151.

S4.5.4. Dinov B, Fiedler L, Schönbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) study. Circulation 2014;129:728–736.

S4.5.5. Tokuda M, Tedrow UB, Kojodjojo P, et al. Catheter ablation of ventricular tachycardia in nonischemic heart disease. Circ Arrhythm Electrophysiol 2012;5:992–1000.

S4.5.6. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm 2015;12:1997–2007.

S4.5.7. Muser D, Liang JJ, Pathak RK, et al. Long-term outcomes of catheter ablation of electrical storm in nonischemic dilated cardiomyopathy compared with ischemic cardiomyopathy. JACC Clin Electrophysiol 2017;3:767–778.

S4.5.8. Arya A, Bode K, Piorkowski C, et al. Catheter ablation of electrical storm due to monomorphic ventricular tachycardia in patients with nonischemic cardiomyopathy: acute results and its effect on long-term survival. Pacing Clin Electrophysiol 2010;33:1504–1509.

S4.5.9. Carbucicchio C, Santamaria M, Trevisi N, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators: short- and long-term outcomes in a prospective single-center study. Circulation 2008;117:462–469.

S4.5.10. Hu J, Zeng S, Zhou Q, et al. Can ventricular tachycardia non-inducibility after ablation predict reduced ventricular tachycardia recurrence and mortality in patients with non-ischemic cardiomyopathy? A meta-analysis of twenty-four observational studies. Int J Cardiol 2016;222:689–695.

S4.5.11. Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia: a European multicenter study. Circ Arrhythm Electrophysiol 2011;4:653–659.

S4.5.12. Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. J Am Coll Cardiol 2010;55:2366–2372.

S4.5.13. Cano O, Hutchinson M, Lin D, et al. Electroanatomic substrate and ablation outcome for suspected epicardial ventricular tachycardia in left ventricular nonischemic cardiomyopathy. J Am Coll Cardiol 2009;54:799–808.

S4.5.14. Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 2009;6:189–195.

S4.5.15. Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2014;7:407–413.

S4.5.16. Kumar S, Barbhaiya C, Nagashima K, et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015;8:87–93.

S4.5.17. Muser D, Santangeli P, Pathak RK, et al. Long-term outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2016;9:e004333.

S4.5.18. Papageorgiou N, Providência R, Bronis K, et al. Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: a systematic review. Europace 2018;20:682–691.

S4.5.19. Kumar S, Androulakis AF, Sellal JM, et al. Multicenter experience with catheter ablation for ventricular tachycardia in lamin A/C cardiomyopathy. Circ Arrhythm Electrophysiol 2016;9:e004357.

4.6. Ventricular Arrhythmia Involving the His-Purkinje System, Bundle Branch Reentrant Ventricular Tachycardia, and Fascicular Ventricular Tachycardia

Recommendations for catheter ablation of bundle branch reentrant VT and for catheter ablation of fascicular VT

COR	LOE	Recommendations	References
I	B-NR	1. In patients with bundle branch reentrant VT, catheter ablation is useful for reducing the risk of recurrent VT.	S4.6.1–S4.6.9
I	B-NR	2. In patients with idiopathic left fascicular reentrant VT for whom medications are ineffective, not tolerated, or not the patient's preference, catheter ablation is useful.	S4.6.10–S4.6.22
I	B-NR	3. In larger pediatric patients (≥15 kg) with idiopathic left fascicular reentrant VT in whom medical treatment is ineffective or not tolerated, catheter ablation is useful.	S4.6.23–S4.6.26
I	B-NR	4. In patients with focal fascicular VT with or without SHD, catheter ablation is useful.	S4.6.11,S4.6.27–S4.6.29
I	B-NR	5. In patients with postinfarction reentrant Purkinje fiber-mediated VT, catheter ablation is useful.	S4.6.30–S4.6.32

References

S4.6.1. Cohen TJ, Chien WW, Lurie KG, et al. Radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia: results and long-term follow-up. J Am Coll Cardiol 1991;18:1767–1773.

S4.6.2. Blank Z, Dhala A, Deshpande S, Sra J, Jazayeri M, Akhtar M. Bundle branch reentrant ventricular tachycardia: Cumulative experience in 48 patients. J Cardiovasc Electrophysiol 1993;4:253–262.

S4.6.3. Mehdirad AA, Keim S, Rist K, Tchou P. Long-term clinical outcome of right bundle branch radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia. Pacing Clin Electrophysiol 1995; 18(12 Pt 1):2135–2143.

S4.6.4. Pathak RK, Fahed J, Santangeli P, et al. Long-term outcome of catheter ablation for treatment of bundle branch re-entrant tachycardia. JACC Clin Electrophysiol 2018;4:331–338.

S4.6.5. Narasimhan C, Jazayeri MR, Sra J, et al. Ventricular tachycardia in valvular heart disease: facilitation of bundle-branch reentry by valve surgery. Circulation 1997;96:4307–4313.

S4.6.6. Li YG, Grönefeld G, Israel C, Bogun F, Hohnloser SH. Bundle branch reentrant tachycardia in patients with apparent normal His-Purkinje conduction: the role of functional conduction impairment. J Cardiovasc Electrophysiol 2002;13:1233–1239.

S4.6.7. Schmidt B, Tang M, Chun KR, et al. Left bundle branch-Purkinje system in patients with bundle branch reentrant tachycardia: lessons from catheter ablation and electroanatomic mapping. Heart Rhythm 2009;6:51–58.

S4.6.8. Blanck Z, Jazayeri M, Dhala A, Deshpande S, Sra J, Akhtar M. Bundle branch reentry: a mechanism of ventricular tachycardia in the absence of myocardial or valvular dysfunction. J Am Coll Cardiol 1993; 22:1718–1722.

S4.6.9. Chen H, Shi L, Yang B, et al. Electrophysiological characteristics of bundle branch reentry ventricular tachycardia in patients without structural heart disease. Circ Arrhythm Electrophysiol 2018;11:e006049.

S4.6.10. Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and presystolic Purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J Am Coll Cardiol 2000;36:811–823.

S4.6.11. Ouyang F, Cappato R, Ernst S, et al. Electroanatomic substrate of idiopathic left ventricular tachycardia: unidirectional block and macroreentry within the Purkinje network. Circulation 2002;105:462–469.

S4.6.12. Liu Y, Fang Z, Yang B, et al. Catheter ablation of fascicular ventricular tachycardia: long-term clinical outcomes and mechanisms of recurrence. Circ Arrhythm Electrophysiol 2015;8:1443–1451.

S4.6.13. Nakagawa H, Beckman KJ, McClelland JH, et al. Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential. Circulation 1993;88:2607–2617.

S4.6.14. Chen M, Yang B, Zou J, et al. Non-contact mapping and linear ablation of the left posterior fascicle during sinus rhythm in the treatment of idiopathic left ventricular tachycardia. Europace 2005;7:138–144.

S4.6.15. Kottkamp H, Chen X, Hindricks G, et al. Idiopathic left ventricular tachycardia: new insights into electrophysiological characteristics and radiofrequency catheter ablation. Pacing Clin Electrophysiol 1995; 18:1285–1297.

S4.6.16. Lin D, Hsia HH, Gerstenfeld EP, et al. Idiopathic fascicular left ventricular tachycardia: linear ablation lesion strategy for noninducible or nonsustained tachycardia. Heart Rhythm 2005;2:934–939.

S4.6.17. Tada H, Nogami A, Naito S, et al. Retrograde Purkinje potential activation during sinus rhythm following catheter ablation of idiopathic left ventricular tachycardia. J Cardiovasc Electrophysiol 1998;9:1218–1224.

S4.6.18. Tsuchiya T, Okumura K, Honda T, et al. Significance of late diastolic potential preceding Purkinje potential in verapamil-sensitive idiopathic left ventricular tachycardia. Circulation 1999;99:2408–2413.

S4.6.19. Wen MS, Yeh SJ, Wang CC, Lin FC, Wu D. Successful radiofrequency ablation of idiopathic left ventricular tachycardia at a site away from the tachycardia exit. J Am Coll Cardiol 1997;30:1024–1031.

S4.6.20. Arya A, Haghjoo M, Emkanjoo Z, et al. Comparison of presystolic Purkinje and late diastolic potentials for selection of ablation site in idiopathic verapamil sensitive left ventricular tachycardia. J Interv Card Electrophysiol 2004; 11:135–141.

S4.6.21. Liu Q, Shehata M, Jiang R, et al. Macroreentrant loop in ventricular tachycardia from the left posterior fascicle: new implications for mapping and ablation. Circ Arrhythm Electrophysiol 2016;9:e004272.

S4.6.22. Guo XG, Liu X, Zhou GB, et al. Clinical, electrocardiographic, and electrophysiological characteristics of left upper septal fascicular ventricular tachycardia. Europace 2018;20:673–681.

S4.6.23. Collins KK, Schaffer MS, Liberman L, et al. Fascicular and nonfascicular left ventricular tachycardias in the young: an international multicenter study. J Cardiovasc Electrophysiol 2013;24:640–648.

S4.6.24. Suzuki T, Nakamura Y, Yoshida S, et al. Radiofrequency catheter ablation of idiopathic left anterior fascicular ventricular tachycardia in children. Heart Rhythm 2014;11:1948–1956.

S4.6.25. Fishberger SB, Olen MM, Rollinson NL, Rossi AF. Creation of partial fascicular block: an approach to ablation of idiopathic left ventricular tachycardia in the pediatric population. Pacing Clin Electrophysiol 2015; 38:209–215.

S4.6.26. Saul JP, Kanter RJ, Abrams D, et al. PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease: developed in partnership with the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American Academy of Pediatrics (AAP), the American Heart Association (AHA), and the Association for European Pediatric and Congenital Cardiology (AEPC). Heart Rhythm 2016;13:e251–e289.

S4.6.27. Talib AK, Nogami A, Morishima I, et al. Non-reentrant fascicular tachycardia: clinical and electrophysiological characteristics of a distinct type of idiopathic ventricular tachycardia. Circ Arrhythm Electrophysiol 2016; 9:e004177.

S4.6.28. Lopera G, Stevenson WG, Soejima K, et al. Identification and ablation of three types of ventricular tachycardia involving the His-Purkinje system in patients with heart disease. J Cardiovasc Electrophysiol 2004;15:52–58.

S4.6.29. Gonzalez RP, Scheinman MM, Lesh MD, Helmy I, Torres V, Van Hare GF. Clinical and electrophysiologic spectrum of fascicular tachycardias. Am Heart J 1994;128:147–156.

S4.6.30. Nogami A. Purkinje-related arrhythmias. Part I: monomorphic ventricular tachycardias. Pacing Clin Electrophysiol 2011;34:624–650.

S4.6.31. Hayashi M, Kobayashi Y, Iwasaki YK, et al. Novel mechanism of postinfarction ventricular tachycardia originating in surviving left posterior Purkinje fibers. Heart Rhythm 2006;3:908–918.

S4.6.32. Bogun F, Good E, Reich S, et al. Role of Purkinje fibers in post-infarction ventricular tachycardia. J Am Coll Cardiol 2006;48:2500–2507.

4.7. Congenital Heart Disease

Recommendations for catheter ablation of VA in patients with CHD			
COR	LOE	Recommendations	References
I	B-NR	1. In patients with CHD presenting with sustained VAs, evaluation for potential residual anatomical or coronary abnormalities should be performed.	S4.7.1–S4.7.6
I	B-NR	2. In patients with CHD presenting with sustained VT in the presence of important hemodynamic lesions, treatment of hemodynamic abnormalities as feasible should be performed in conjunction with consideration for ablation.	S4.7.2,S4.7.7–S4.7.16
I	B-NR	3. In patients with repaired tetralogy of Fallot and sustained monomorphic VT or recurrent appropriate ICD therapy for VAs, catheter ablation is effective.	S4.7.17–S4.7.24
IIa	B-NR	4. In select patients with CHD and clinical episodes of sustained VT who are undergoing surgical repair of residual hemodynamic abnormalities, surgical ablation of VT guided by preoperative or intraoperative electroanatomical mapping (EAM) can be beneficial.	S4.7.2,S4.7.8, S4.7.9,S4.7.11, S4.7.25




Figure 2 Congenital heart disease and sustained VT. For further discussion of ICD candidacy, please see *PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease* (S4.7.14) and *2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities* (S4.7.26). ACA = aborted cardiac arrest; CHD = congenital heart disease; DORV = double outlet right ventricle; ICD = implantable cardioverter defibrillator; TOF = tetralogy of Fallot; VT = ventricular tachycardia.

References

S4.7.1. Gatzoulis MA, Till JA, Somerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation 1995;92:231–237.

S4.7.2. Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol 1997;30:1368–1373.

S4.7.3. Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart 2008;94:211–216.

S4.7.4. Diller GP, Kempny A, Liodakis E, et al. Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in adults with repaired tetralogy of Fallot. Circulation 2012;125:2440–2446.

S4.7.5. Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation 2012;126:1944–1954.

S4.7.6. Koyak Z, de Groot JR, Bouma BJ, et al. Sudden cardiac death in adult congenital heart disease: can the unpredictable be foreseen? Europace 2017;19:401–406.

S4.7.7. Deal BJ, Scagliotti D, Miller SM, Gallastegui JL, Hariman RJ, Levitsky S. Electrophysiologic drug testing in symptomatic ventricular arrhythmias after repair of tetralogy of Fallot. Am J Cardiol 1987;59:1380–1385.

S4.7.8. Oechslin EN, Harrison DA, Harris L, et al. Reoperation in adults with repair of tetralogy of Fallot: indications and outcomes. J Thorac Cardiovasc Surg 1999;118:245–251.

S4.7.9. Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation 2001;103:2489–2494.

S4.7.10. Therrien J, Provost Y, Merchant N, Williams W, Colman J, Webb G. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol 2005;95:779–782.

S4.7.11. Mavroudis C, Deal BJ, Backer CL, Tsao S. Arrhythmia surgery in patients with and without congenital heart disease. Ann Thorac Surg 2008;86:857–868.

S4.7.12. Adamson L, Vohra HA, Haw MP. Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? Interact Cardiovasc Thorac Surg 2009;9:520–527.

S4.7.13. Miyazaki A, Sakaguchi H, Ohuchi H, et al. Efficacy of hemodynamic-based management of tachyarrhythmia after repair of tetralogy of Fallot. Circ J 2012;76:2855–2862.

S4.7.14. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Heart Rhythm 2014;11:e102–e165.

S4.7.15. Lin YS, Liu PH, Wu LS, Chen YM, Chang CJ, Chu PH. Major adverse cardiovascular events in adult congenital heart disease: a population-based follow-up study from Taiwan. BMC Cardiovasc Disord 2014;14:38.

S4.7.16. Sabate Rotes A, Connolly HM, Warnes CA, et al. Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol 2015;8:110–116.

S4.7.17. Gonska BD, Cao K, Raab J, Eigster G, Kreuzer H. Radiofrequency catheter ablation of right ventricular tachycardia late after repair of congenital heart defects. Circulation 1996;94:1902–1908.

S4.7.18. Morwood JG, Triedman JK, Berul CI, et al. Radiofrequency catheter ablation of ventricular tachycardia in children and young adults with congenital heart disease. Heart Rhythm 2004;1:301–308.

S4.7.19. Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation 2007;116:2241–2252.

S4.7.20. Kriebel T, Saul JP, Schneider H, Sigler M, Paul T. Noncontact mapping and radiofrequency catheter ablation of fast and hemodynamically unstable ventricular tachycardia after surgical repair of tetralogy of Fallot. J Am Coll Cardiol 2007;50:2162–2168.

S4.7.21. Kapel GF, Reichlin T, Wijnmaalen AP, et al. Left-sided ablation of ventricular tachycardia in adults with repaired tetralogy of Fallot: a case series. Circ Arrhythm Electrophysiol 2014;7:889–897.

S4.7.22. Kapel GF, Reichlin T, Wijnmaalen AP, et al. Re-entry using anatomically determined isthmuses: a curable ventricular tachycardia in repaired congenital heart disease. Circ Arrhythm Electrophysiol 2015;8:102–109.

S4.7.23. van Zyl M, Kapa S, Padmanabhan D, et al. Mechanism and outcomes of catheter ablation for ventricular tachycardia in adults with repaired congenital heart disease. Heart Rhythm 2016;13:1449–1454.

S4.7.24. Kapel GF, Sacher F, Dekkers OM, et al. Arrhythmogenic anatomical isthmuses identified by electroanatomical mapping are the substrate for ventricular tachycardia in repaired tetralogy of Fallot. Eur Heart J 2017;38:268–276.

S4.7.25. Sandhu A, Ruckdeschel E, Sauer WH, et al. Perioperative electrophysiology study in patients with tetralogy of Fallot undergoing pulmonary valve replacement will identify those at high risk of subsequent ventricular tachycardia. Heart Rhythm 2018;15:679–685.

S4.7.26. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2012;9:1737–1753.

4.8. Inherited Arrhythmia Syndromes

Recommendations for catheter ablation of VA in inherited primary arrhythmia disorders

COR	LOE	Recommendations	References
I	B-NR	**1. In patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) who experience recurrent sustained VT or frequent appropriate ICD interventions for VT in whom AAD therapy is ineffective or not tolerated, catheter ablation, at a center with specific expertise, is recommended.**	S4.8.1–S4.8.11
I	B-NR	**2. In patients with ARVC who have failed one or more attempts of endocardial VT catheter ablation, an epicardial approach for VT ablation is recommended.**	S4.8.3–S4.8.7,S4.8.12,S4.8.13
IIa	B-NR	**3. In patients with ARVC who experience recurrent sustained VT or frequent appropriate ICD interventions for VT in whom AAD therapy is not desired or preferred, catheter ablation, at a center with specific expertise, is reasonable.**	S4.8.1,S4.8.3–S4.8.6,S4.8.8
IIa	B-NR	**4. In patients with Brugada syndrome who experience recurrent sustained VAs or frequent appropriate ICD interventions, catheter ablation can be useful.**	S4.8.14–S4.8.17
IIa	C-LD	**5. In patients with ARVC, a first-line combined endocardial/epicardial approach for VT ablation is reasonable.**	S4.8.1,S4.8.6,S4.8.12,S4.8.18

References

S4.8.1. Berruezo A, Acosta J, Fernández-Armenta J, et al. Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study. Europace 2017;19:607–616.

S4.8.2. Jiang H, Zhang X, Yang Q, et al. Catheter ablation for ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: a systematic review and meta-analysis. Acta Cardiol 2016; 71:639–649.

S4.8.3. Philips B, te Riele AS, Sawant A, et al. Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2015;12:716–725.

S4.8.4. Santangeli P, Zado ES, Supple GE, et al. Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 2015; 8:1413–1421.

S4.8.5. Philips B, Madhavan S, James C, et al. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol 2012;5:499–505.

S4.8.6. Bai R, Di Biase L, Shivkumar K, et al. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation. Circ Arrhythm Electrophysiol 2011;4:478–485.

S4.8.7. Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2009; 120:366–375.

S4.8.8. Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2007;50:432–440.

S4.8.9. Verma A, Kilicaslan F, Schweikert RA, et al. Short- and long-term success of substrate-based mapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia. Circulation 2005;111:3209–3216.

S4.8.10. Marchlinski FE, Zado E, Dixit S, et al. Electroanatomic substrate and outcome of catheter ablative therapy for ventricular tachycardia in setting of right ventricular cardiomyopathy. Circulation 2004;110:2293–2298.

S4.8.11. Nogami A, Sugiyasu A, Tada H, et al. Changes in the isolated delayed component as an endpoint of catheter ablation in arrhythmogenic right ventricular cardiomyopathy: predictor for long-term success. J Cardiovasc Electrophysiol 2008;19:681–688.

S4.8.12. Müssigbrodt A, Efimova E, Knopp H, et al. Should all patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergo epicardial catheter ablation? J Interv Card Electrophysiol 2017;48:193–199.

S4.8.13. Pokushalov E, Romanov A, Turov A, Artyomenko S, Shirokova N, Karaskov A. Percutaneous epicardial ablation of ventricular tachycardia after failure of endocardial approach in the pediatric population with arrhythmogenic right ventricular dysplasia. Heart Rhythm 2010;7:1406–1410.

S4.8.14. Pappone C, Brugada J, Vicedomini G, et al. Electrical substrate elimination in 135 consecutive patients with Brugada syndrome. Circ Arrhythm Electrophysiol 2017;10:e005053.

S4.8.15. Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phenotype elimination by epicardial substrate ablation. Circ Arrhythm Electrophysiol 2015;8:1373–1381.

S4.8.16. Zhang P, Tung R, Zhang Z, et al. Characterization of the epicardial substrate for catheter ablation of Brugada syndrome. Heart Rhythm 2016; 13:2151–2158.

S4.8.17. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011; 123:1270–1279.

S4.8.18. Berruezo A, Fernández-Armenta J, Mont L, et al. Combined endocardial and epicardial catheter ablation in arrhythmogenic right ventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm Electrophysiol 2012;5:111–121.

4.9. Ventricular Arrhythmia in Hypertrophic Cardiomyopathy

Recommendation for VA ablation in hypertrophic cardiomyopathy (HCM)

COR	LOE	Recommendation	References
IIa	B-NR	**1. In patients with HCM and recurrent monomorphic VT in whom AAD therapy is ineffective or not tolerated, catheter ablation can be useful.**	S4.9.1–S4.9.5

References

S4.9.1. Dukkipati SR, d'Avila A, Soejima K, et al. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2011;4:185–194.

S4.9.2. Santangeli P, Di Biase L, Lakkireddy D, et al. Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility. Heart Rhythm 2010;7:1036–1042.

S4.9.3. Ueda A, Fukamizu S, Soejima K, et al. Clinical and electrophysiological characteristics in patients with sustained monomorphic reentrant ventricular tachycardia associated with dilated-phase hypertrophic cardiomyopathy. Europace 2012;14:734–740.

S4.9.4. Inada K, Seiler J, Roberts-Thomson KC, et al. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2011; 22:41–48.

S4.9.5. Igarashi M, Nogami A, Kurosaki K, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm. JACC Clin Electrophysiol 2018;4:339–350.

Section 5 Procedural Planning

This section includes preprocedural risk assessment (Table 4), preprocedural patient preparation, and preprocedural arrhythmia documentation with a focus on the regionalizing information of the ECG regarding the origin of VAs (Figures 3 and 4). Furthermore, the capabilities of multimodality imaging in localizing the arrhythmogenic substrate are discussed in detail. Topics including the required equipment, personnel, and facility are detailed in this section.

Table 4 The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation

Variable	Points
Pulmonary disease (COPD)	5
Age >60	3
General **a**nesthesia	4
Ischemic cardiomyopathy	6
NYHA class III/IV	6
EF <25%	3
VT **s**torm	5
Diabetes mellitus	3

The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation, has values that range from 0 to 35 points (or 0 to 31 [PAINESD] when the modifiable intraprocedural variable "general anesthesia" is excluded) (Santangeli et al. Circ Arrhythm Electrophysiol 2015;8:68–75). COPD = chronic obstructive pulmonary disease; EF = ejection fraction; NYHA = New York Heart Association; VT = ventricular tachycardia.




Figure 3 Examples of 12-lead ECGs of premature ventricular complexes from different LV sites, as corroborated by successful focal ablation. (A) shows 12-lead ECG patterns of common ventricular arrhythmia origins in patients without SHD [1–9] from the left ventricle. All leads are displayed at the same amplification and sweep speed. These locations are illustrated in (B) based on 3D reconstruction of a cardiac computed tomography using the MUSIC software that was developed at the University of Bordeaux. The reconstruction shows an anterolateral view of the left ventricle, aorta, and left atrium. Also shown are the coronary arteries (red), the coronary venous system (blue), and the phrenic nerve (green). AIV = anterior interventricular vein; AL PAP = anterolateral papillary muscle; AMC = aortomitral continuity; ECG = electrocardiogram; GCV = great cardiac vein; ant. MA = anterior mitral valve annulus; PM PAP = posteromedial papillary muscle; R/L = right-left; SHD = structural heart disease; SoV = sinus of Valsalva.




Figure 4 Examples of 12-lead ECGs of premature ventricular complexes from different right ventricular sites, as corroborated by successful focal ablation. All leads are displayed at the same amplification and sweep speed. (A) shows the 12-lead ECG pattern of common origins of right ventricular arrhythmias in patients without SHD [1–6]. The locations are detailed in a 3D reconstruction of the computed tomography using the MUSIC software that was developed at the University of Bordeaux. The reconstruction shown in (B) illustrates the septal view of the right ventricle. Indicated are the pulmonary artery, the tricuspid valve annulus, and the right ventricular apex. ECG = electrocardiogram; PA = pulmonary artery; RVOT= right ventricular outflow tract; SHD = structural heart disease; TVA = tricuspid valve annulus.

Recommendations for preprocedural imaging for VA catheter ablation

COR	LOE	Recommendations	References
I	B-NR	**1. In patients with LV dysfunction undergoing catheter ablation of VA, preprocedural or intraprocedural imaging is recommended to rule out cardiac thrombi.**	S5.1–S5.6
IIa	B-NR	**2. In patients with NICM or ischemic cardiomyopathy (ICM) undergoing catheter ablation of VT, preprocedural CMR can be useful to reduce VT recurrence.**	S5.7–S5.9
IIa	B-NR	**3. In patients with NICM or ICM undergoing catheter ablation of VA, preprocedural imaging can be useful for procedural planning.**	S5.10–S5.26
IIa	C-EO	**4. In patients with NICM, CMR can be useful prior to ICD implantation to allow imaging without device-related artifact for diagnostic purposes and identification of potential arrhythmogenic substrate.**	
IIb	C-EO	**5. In patients with ICM, CMR may be considered prior to ICD implantation to allow imaging without device-related artifact for identification of the potential arrhythmogenic substrate.**	

References

S5.1. Visser CA, Kan G, David GK, Lie KI, Durrer D. Two dimensional echocardiography in the diagnosis of left ventricular thrombus: a prospective study of 67 patients with anatomic validation. Chest 1983;83:228–232.

S5.2. Ezekowitz MD, Wilson DA, Smith EO, et al. Comparison of Indium-111 platelet scintigraphy and two-dimensional echocardiography in the diagnosis of left ventricular thrombi. N Engl J Med 1982;306:1509–1513.

S5.3. Stratton JR, Lighty GW Jr, Pearlman AS, Ritchie JL. Detection of left ventricular thrombus by two-dimensional echocardiography: sensitivity, specificity, and causes of uncertainty. Circulation 1982;66:156–166.

S5.4. Thanigaraj S, Schechtman KB, Perez JE. Improved echocardiographic delineation of left ventricular thrombus with the use of intravenous second-generation contrast image enhancement. J Am Soc Echocardiogr 1999;12:1022–1026.

S5.5. Weinsaft JW, Kim HW, Shah DJ, et al. Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol 2008; 52:148–157.

S5.6. Weinsaft JW, Kim RJ, Ross M, et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc Imaging 2009;2:969–979.

S5.7. Siontis KC, Kim HM, Sharaf Dabbagh G, et al. Association of preprocedural cardiac magnetic resonance imaging with outcomes of ventricular tachycardia ablation in patients with idiopathic dilated cardiomyopathy. Heart Rhythm 2017;14:1487–1493.

S5.8. Zghaib T, Ipek EG, Hansford R, et al. Standard ablation versus magnetic resonance imaging-guided ablation in the treatment of ventricular tachycardia. Circ Arrhythm Electrophysiol 2018;11:e005973.

S5.9. Andreu D, Penela D, Acosta J, et al. Cardiac magnetic resonance-aided scar dechanneling: Influence on acute and long-term outcomes. Heart Rhythm 2017;14:1121–1128.

S5.10. Codreanu A, Odille F, Aliot E, et al. Electroanatomic characterization of postinfarct scars comparison with 3-dimensional myocardial scar reconstruction based on magnetic resonance imaging. J Am Coll Cardiol 2008;52:839–842.

S5.11. Desjardins B, Crawford T, Good E, et al. Infarct architecture and characteristics on delayed enhanced magnetic resonance imaging and electroanatomic mapping in patients with postinfarction ventricular arrhythmia. Heart Rhythm 2009;6:644–651.

S5.12. Bogun FM, Desjardins B, Good E, et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol 2009;53:1138–1145.

S5.13. Dickfeld T, Tian J, Ahmad G, et al. MRI-guided ventricular tachycardia ablation: integration of late gadolinium-enhanced 3D scar in patients with implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 2011;4:172–184.

S5.14. Fernandez-Armenta J, Berruezo A, Andreu D, et al. Three-dimensional architecture of scar and conducting channels based on high resolution ce-CMR: insights for ventricular tachycardia ablation. Circ Arrhythm Electrophysiol 2013;6:528–537.

S5.15. Gupta S, Desjardins B, Baman T, et al. Delayed-enhanced MR scar imaging and intraprocedural registration into an electroanatomical mapping system in post-infarction patients. JACC Cardiovasc Imaging 2012;5:207–210.

S5.16. Marra MP, Leoni L, Bauce B, et al. Imaging study of ventricular scar in arrhythmogenic right ventricular cardiomyopathy: comparison of 3D standard electroanatomical voltage mapping and contrast-enhanced cardiac magnetic resonance. Circ Arrhythm Electrophysiol 2012;5:91–100.

S5.17. Nakahara S, Vaseghi M, Ramirez RJ, et al. Characterization of myocardial scars: electrophysiological imaging correlates in a porcine infarct model. Heart Rhythm 2011;8:1060–1067.

S5.18. Ghannam M, Cochet H, Jais P, et al. Correlation between computer tomography-derived scar topography and critical ablation sites in postinfarction ventricular tachycardia. J Cardiovasc Electrophysiol 2018;29:438–445.

S5.19. Esposito A, Palmisano A, Antunes S, et al. Cardiac CT with delayed enhancement in the characterization of ventricular tachycardia structural substrate: relationship between CT-segmented scar and electro-anatomic mapping. JACC Cardiovasc Imaging 2016;9:822–832.

S5.20. Tian J, Jeudy J, Smith MF, et al. Three-dimensional contrast-enhanced multidetector CT for anatomic, dynamic, and perfusion characterization of abnormal myocardium to guide ventricular tachycardia ablations. Circ Arrhythm Electrophysiol 2010;3:496–504.

S5.21. Yamashita S, Sacher F, Mahida S, et al. Image integration to guide catheter ablation in scar-related ventricular tachycardia. J Cardiovasc Electrophysiol 2016;27:699–708.

S5.22. Komatsu Y, Cochet H, Jadidi A, et al. Regional myocardial wall thinning at multidetector computed tomography correlates to arrhythmogenic substrate in postinfarction ventricular tachycardia: assessment of structural and electrical substrate. Circ Arrhythm Electrophysiol 2013;6:342–350.

S5.23. Dickfeld T, Lei P, Dilsizian V, et al. Integration of three-dimensional scar maps for ventricular tachycardia ablation with positron emission tomography-computed tomography. JACC Cardiovasc Imaging 2008;1:73–82.

S5.24. Tian J, Smith MF, Chinnadurai P, et al. Clinical application of PET/CT fusion imaging for three-dimensional myocardial scar and left ventricular anatomy during ventricular tachycardia ablation. J Cardiovasc Electrophysiol 2009; 20:567–604.

S5.25. Andreu D, Ortiz-Perez JT, Boussy T, et al. Usefulness of contrast-enhanced cardiac magnetic resonance in identifying the ventricular arrhythmia substrate and the approach needed for ablation. Eur Heart J 2014;35:1316–1326.

S5.26. Soto-Iglesias D, Acosta J, Penela D, et al. Image-based criteria to identify the presence of epicardial arrhythmogenic substrate in patients with transmural myocardial infarction. Heart Rhythm 2018;15:814–821.

Section 6 Intraprocedural Patient Care

Important aspects regarding intraprocedural sedation and its potential problems are highlighted in this section. Furthermore, vascular access, epicardial access with its many potential complications are discussed in detail, as well as anticoagulation and the indications for the use of hemodynamic support (HS) during VT ablation procedures.

6.1. Anesthesia

Recommendations for anesthesia during catheter ablation of VA			
COR	LOE	Recommendations	References
I	C-EO	1. Provision of variable depth of sedation, analgesia, and anesthesia during mapping and ablation of VA is recommended.	
I	C-EO	2. In patients undergoing VA ablation, careful preprocedural assessment is indicated to define the ideal strategy for sedation and analgesia.	
IIa	C-LD	3. It is reasonable to avoid general anesthesia and deeper levels of sedation in patients with idiopathic VA, particularly if the arrhythmia is suspected to be catecholamine-sensitive or was not inducible at a prior procedure.	S6.1.1
IIb	B-NR	4. Moderate to deep sedation under close hemodynamic and respiratory monitoring might be considered for VA ablation in stable patients with idiopathic or scar-related VAs expected to have a longer procedure or undergo a painful technique, such as epicardial access.	S6.1.1–S6.1.3

References

S6.1.1. Wutzler A, Mueller A, Loehr L, et al. Minimal and deep sedation during ablation of ventricular tachycardia. Int J Cardiol 2014;172:161–164.

S6.1.2. Servatius H, Höfeler T, Hoffmann BA, et al. Propofol sedation administered by cardiologists for patients undergoing catheter ablation for ventricular tachycardia. Europace 2016;18:1245–1251.

S6.1.3. Nazer B, Woods C, Dewland T, Moyers B, Badhwar N, Gerstenfeld EP. Importance of ventricular tachycardia induction and mapping for patients referred for epicardial ablation. Pacing Clin Electrophysiol 2015;38:1333–1342.

6.2. Vascular Access

Recommendation for vascular access during catheter ablation of VA			
COR	LOE	Recommendation	References
I	B-NR	1. Ultrasound-guided femoral arterial and venous access is recommended to reduce the incidence of vascular access complications during VA ablation.	S6.2.1–S6.2.5

References

S6.2.1. Sharma PS, Padala SK, Gunda S, Koneru JN, Ellenbogen KA. Vascular complications during catheter ablation of cardiac arrhythmias: a comparison between vascular ultrasound guided access and conventional vascular access. J Cardiovasc Electrophysiol 2016;27:1160–1166.

S6.2.2. Tanaka-Esposito CC, Chung MK, Abraham JM, Cantillon DJ, Abi-Saleh B, Tchou PJ. Real-time ultrasound guidance reduces total and major vascular complications in patients undergoing pulmonary vein antral isolation on therapeutic warfarin. J Interv Card Electrophysiol 2013;37:163–168.

S6.2.3. Yamagata K, Wichterle D, Roubíček T, et al. Ultrasound-guided versus conventional femoral venipuncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ULTRA-FAST trial). Europace 2018;20:1107–1114.

S6.2.4. Sobolev M, Shiloh AL, Di Biase L, Slovut DP. Ultrasound-guided cannulation of the femoral vein in electrophysiological procedures: a systematic review and meta-analysis. Europace 2017;19:850–855.

S6.2.5. Seto AH, Abu-Fadel MS, Sparling JM, et al. Real-time ultrasound guidance facilitates femoral arterial access and reduces vascular complications: FAUST (Femoral Arterial Access With Ultrasound Trial). JACC Cardiovasc Interv 2010;3:751–758.

6.3. Epicardial Access

Recommendations for epicardial access for catheter ablation		
COR	LOE	Recommendations
I	C-EO	1. In patients undergoing epicardial VT ablation, imaging of the epicardial coronary arteries by coronary arteriography or coronary computed tomography angiogram prior to ablation is recommended to reduce the risk of arterial injury.
I	C-EO	2. In patients undergoing epicardial VT ablation via a percutaneous approach, provision for immediate echocardiography, blood transfusion, and onsite cardiothoracic surgical backup is recommended.
I	C-EO	3. In patients with prior cardiac surgery or pericardial adhesions for whom epicardial VT ablation via a percutaneous approach is considered, careful assessment of the risk/benefit ratio and alternative therapies such as surgical dissection are recommended.
I	C-EO	4. In patients undergoing epicardial VT ablation, pacing with high stimulus intensity from the ablation electrode to rule out diaphragmatic stimulation is recommended to avoid phrenic nerve injury.

6.4. Intraprocedural Hemodynamic Support

Recommendations for catheter ablation of VA with mechanical HS

COR	LOE	Recommendations	References
I	C-EO	1. In select patients at risk of requiring HS, a decision to proceed with catheter ablation of VA should be made in collaboration with specialists in advanced heart failure management.	
IIa	B-NR	2. In select patients, HS with a percutaneous ventricular assist device and extracorporeal membrane oxygenation during VT ablation can be useful to avoid acute hemodynamic deterioration.	S6.4.1–S6.4.7
IIb	B-NR	3. Mechanical HS may be considered in select cases to allow mapping and ablation of unstable VTs.	S6.4.1–S6.4.6

References

S6.4.1. Miller MA, Dukkipati SR, Mittnacht AJ, et al. Activation and entrainment mapping of hemodynamically unstable ventricular tachycardia using a percutaneous left ventricular assist device. J Am Coll Cardiol 2011;58:1363–1371.

S6.4.2. Reddy YM, Chinitz L, Mansour M, et al. Percutaneous left ventricular assist devices in ventricular tachycardia ablation: multicenter experience. Circ Arrhythm Electrophysiol 2014;7:244–250.

S6.4.3. Baratto F, Pappalardo F, Oloriz T, et al. Extracorporeal membrane oxygenation for hemodynamic support of ventricular tachycardia ablation. Circ Arrhythm Electrophysiol 2016;9:e004492.

S6.4.4. Kusa S, Miller MA, Whang W, et al. Outcomes of ventricular tachycardia ablation using percutaneous left ventricular assist devices. Circ Arrhythm Electrophysiol 2017;10:e004717.

S6.4.5. Mathuria N, Wu G, Rojas-Delgado F, et al. Outcomes of pre-emptive and rescue use of percutaneous left ventricular assist device in patients with structural heart disease undergoing catheter ablation of ventricular tachycardia. J Interv Card Electrophysiol 2017;48:27–34.

S6.4.6. Turagam MK, Vuddanda V, Atkins D, et al. Hemodynamic support in ventricular tachycardia ablation: an International VT Ablation Center Collaborative Group Study. JACC Clin Electrophysiol 2017;3:1534–1543.

S6.4.7. Enriquez A, Liang J, Gentile J, et al. Outcomes of rescue cardiopulmonary support for periprocedural acute hemodynamic decompensation in patients undergoing catheter ablation of electrical storm. Heart Rhythm 2018;15:75–80.

6.5. Intraprocedural Anticoagulation

Recommendations for intraprocedural anticoagulation

COR	LOE	Recommendations	References
I	B-NR	1. In patients undergoing endocardial LV catheter mapping and/or ablation, intraprocedural systemic anticoagulation with intravenous heparin is recommended.	S6.5.1–S6.5.6
I	C-EO	2. In patients undergoing RV endocardial mapping and/or ablation who are considered high risk for thromboembolism, intraprocedural systemic anticoagulation with intravenous heparin is recommended.	
IIa	C-LD	3. In patients undergoing epicardial access after systemic heparinization, reversal of heparin with protamine is reasonable.	S6.5.7,S6.5.8

References

S6.5.1. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357:2657–2665.

S6.5.2. Kuck KH, Schaumann A, Eckardt L, et al; VTACH Study Group. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31–40.

S6.5.3. Al-Khatib SM, Daubert JP, Anstrom KJ, et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol 2015;26:151–157.

S6.5.4. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;375:111–121.

S6.5.5. Kuck KH, Tilz RR, Deneke T, et al; SMS Investigators. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol 2017;10:e004422.

S6.5.6. Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol 2000;35:1905–1914.

S6.5.7. Siontis KC, Jamé S, Sharaf Dabbagh G, et al. Thromboembolic prophylaxis protocol with warfarin after radiofrequency catheter ablation of infarct-related ventricular tachycardia. J Cardiovasc Electrophysiol 2018;29:584–590.

S6.5.8. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol 2010;21:47–53.

Section 7 Electrophysiological Testing

The benefits and limitations of PES are detailed in this section.

Section 8 Mapping and Imaging Techniques

8.1. Overview

Activation mapping with multipolar catheters, entrainment mapping (Figures 5 and 6), and pace mapping are the main techniques used to map VAs. This section reviews these techniques including the technique of substrate mapping aiming to identify the arrhythmogenic substrate in sinus rhythm. Furthermore, intraprocedural imaging as it pertains to procedural safety and to identification of the arrhythmogenic substrate is reviewed in this section.




Figure 5 Entrainment responses from components of reentrant VT circuit. CL = cycle length; PPI = postpacing interval; VT = ventricular tachycardia. Adapted with permission from Elsevier (Stevenson et al. J Am Coll Cardiol 1997;29:1180–1189).




Figure 6 Pacing from the protected isthmus of a VT circuit. Entrainment mapping during VT. The VT CL is 620 ms, and pacing is performed at a CL of 580 ms. A low-voltage electrogram is located in diastole on the recordings of the ablation catheter (Map). The stimulus-QRS interval is 230 ms and matches with the electrogram-QRS interval. The postpacing interval is equal to the VT CL. The stimulus-QRS/VT CL ratio is 0.37, indicating that the catheter is located in the common pathway. CL = cycle length; PPI = postpacing interval; VT = ventricular tachycardia.

8.2. Substrate Mapping in Sinus Rhythm

Recommendations for substrate mapping in sinus rhythm			
COR	LOE	Recommendations	References
I	B-NR	1. In patients with scar-related VT, substrate-guided ablation is useful for prevention of arrhythmia recurrences.	S8.2.1–S8.2.11
IIa	B-NR	2. High-density multielectrode mapping to obtain a more comprehensive characterization of the arrhythmogenic tissue during catheter ablation of scar-related VT can be useful.	S8.2.12–S8.2.14
IIa	B-NR	3. In patients with no or minimal endocardial bipolar electrogram abnormalities, reduced unipolar voltage can be useful for detection of epicardial or intramural scar.	S8.2.15–S8.2.19

References

S8.2.1. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357:2657–2665.

S8.2.2. Di Biase L, Burkhardt JD, Lakkireddy D, et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy: the VISTA randomized multicenter trial. J Am Coll Cardiol 2015;66:2872–2882.

S8.2.3. Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol 2000;35:1905–1914.

S8.2.4. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008;118:2773–2782.

S8.2.5. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;375:111–121.

S8.2.6. Kuck K-H, Tilz RR, Deneke T, et al. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol 2017;10:e004422.

S8.2.7. Volkmer M, Ouyang F, Deger F, et al. Substrate mapping vs. tachycardia mapping using CARTO in patients with coronary artery disease and ventricular tachycardia: impact on outcome of catheter ablation. Europace 2006; 8:968–976.

S8.2.8. Makimoto H, Nakajima I, Miyamoto K, et al. Clinical impact of mapping strategies for treatment of ventricular tachycardias in patients with structural heart disease. Pacing Clin Electrophysiol 2015;38:630–640.

S8.2.9. Carbucicchio C, Ahmad Raja N, Di Biase L, et al. High-density substrate-guided ventricular tachycardia ablation: role of activation mapping in an attempt to improve procedural effectiveness. Heart Rhythm 2013;10:1850–1858.

S8.2.10. Briceño DF, Romero J, Villablanca PA, et al. Long-term outcomes of different ablation strategies for ventricular tachycardia in patients with structural heart disease: systematic review and meta-analysis. Europace 2018;20:104–115.

S8.2.11. Kumar S, Baldinger SH, Romero J, et al. Substrate-based ablation versus ablation guided by activation and entrainment mapping for ventricular tachycardia: a systematic review and meta-analysis. J Cardiovasc Electrophysiol 2016;27:1437–1447.

S8.2.12. Acosta J, Penela D, Andreu D, et al. Multielectrode vs. point-by-point mapping for ventricular tachycardia substrate ablation: a randomized study. Europace 2018;20:512–519.

S8.2.13. Berte B, Relan J, Sacher F, et al. Impact of electrode type on mapping of scar-related VT. J Cardiovasc Electrophysiol 2015;26:1213–1223.

S8.2.14. Yamashita S, Cochet H, Sacher F, et al. Impact of new technologies and approaches for post-myocardial infarction ventricular tachycardia ablation during long-term follow-up. Circ Arrhythm Electrophysiol 2016; 9:e003901.

S8.2.15. Hutchinson MD, Gerstenfeld EP, Desjardins B, et al. Endocardial unipolar voltage mapping to detect epicardial ventricular tachycardia substrate in patients with nonischemic left ventricular cardiomyopathy. Circ Arrhythmia Electrophysiol 2011;4:49–55.

S8.2.16. Polin GM, Haqqani H, Tzou W, et al. Endocardial unipolar voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm 2011;8:76–83.

S8.2.17. Chopra N, Tokuda M, Ng J, et al. Relation of the unipolar low-voltage penumbra surrounding the endocardial low-voltage scar to ventricular tachycardia circuit sites and ablation outcomes in ischemic cardiomyopathy. J Cardiovasc Electrophysiol 2014;25:602–608.

S8.2.18. Soto-Becerra R, Bazan V, Bautista W, et al. Ventricular tachycardia in the setting of Chagasic cardiomyopathy. Circ Arrhythm Electrophysiol 2017; 10:e004950.

S8.2.19. Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramural scar in patients with nonischemic cardiomyopathy and relation to intramural ventricular arrhythmias. Circ Arrhythm Electrophysiol 2013; 6:891–897.

8.3. Intraprocedural Imaging During Catheter Ablation of Ventricular Arrhythmias

Recommendations for intraprocedural imaging during catheter ablation of VAs			
COR	LOE	Recommendations	References
I	B-NR	1. Coronary angiography or intracardiac echocardiography (ICE) is recommended to localize the ostia of the coronary arteries prior to ablation within the SV.	S8.3.1–S8.3.4
I	B-NR	2. Coronary angiography is recommended to identify the course of the coronary arteries when ablation is performed in the coronary venous system or in the epicardium.	S8.3.5–S8.3.8
I	B-NR	3. ICE is beneficial to identify and target the papillary muscles with ablation and to assess for catheter stability.	S8.3.9–S8.3.20
I	B-NR	4. ICE or transthoracic echocardiography is useful to assess for pericardial effusion in case of hemodynamic deterioration of the patient.	S8.3.21–S8.3.23
I	C-LD	5. ICE is useful for early recognition of complications, including pericardial effusion.	S8.3.21–S8.3.23
IIb	B-NR	6. ICE may be useful as an adjuvant technique to identify wall segments with wall thinning, wall motion abnormalities, and segments with increased echogenicity, and also to identify intracardiac thrombi.	S8.3.24,S8.3.25

References

S8.3.1. Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp: electrocardiographic characterization for guiding catheter ablation. J Am Coll Cardiol 2002; 39:500–508.

S8.3.2. Hoffmayer KS, Dewland TA, Hsia HH, et al. Safety of radiofrequency catheter ablation without coronary angiography in aortic cusp ventricular arrhythmias. Heart Rhythm 2014;11:1117–1121.

S8.3.3. Hachiya H, Aonuma K, Yamauchi Y, Igawa M, Nogami A, Iesaka Y. How to diagnose, locate, and ablate coronary cusp ventricular tachycardia. J Cardiovasc Electrophysiol 2002;13:551–556.

S8.3.4. Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricular arrhythmias originating from the aortic root prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coll Cardiol 2008;52:139–147.

S8.3.5. Baman TS, Ilg KJ, Gupta SK, et al. Mapping and ablation of epicardial idiopathic ventricular arrhythmias from within the coronary venous system. Circ Arrhythm Electrophysiol 2010;3:274–279.

S8.3.6. Yokokawa M, Latchamsetty R, Good E, et al. Ablation of epicardial ventricular arrhythmias from nonepicardial sites. Heart Rhythm 2011; 8:1525–1529.

S8.3.7. D'Avila A, Gutierrez P, Scanavacca M, et al. Effects of radiofrequency pulses delivered in the vicinity of the coronary arteries: implications for nonsurgical transthoracic epicardial catheter ablation to treat ventricular tachycardia. Pacing Clin Electrophysiol 2002;25:1488–1495.

S8.3.8. Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. J Am Coll Cardiol 2010; 55:2366–2372.

S8.3.9. Good E, Desjardins B, Jongnarangsin K, et al. Ventricular arrhythmias originating from a papillary muscle in patients without prior infarction: a comparison with fascicular arrhythmias. Heart Rhythm 2008;5:1530–1537.

S8.3.10. Yokokawa M, Good E, Desjardins B, et al. Predictors of successful catheter ablation of ventricular arrhythmias arising from the papillary muscles. Heart Rhythm 2010;7:1654–1659.

S8.3.11. Yamada T, McElderry HT, Okada T, et al. Idiopathic focal ventricular arrhythmias originating from the anterior papillary muscle in the left ventricle. J Cardiovasc Electrophysiol 2009;20:866–872.

S8.3.12. Yamada T, Doppalapudi H, McElderry HT, et al. Electrocardiographic and electrophysiological characteristics in idiopathic ventricular arrhythmias originating from the papillary muscles in the left ventricle: relevance for catheter ablation. Circ Arrhythm Electrophysiol 2010;3:324–331.

S8.3.13. Yamada T, Doppalapudi H, McElderry HT, et al. Idiopathic ventricular arrhythmias originating from the papillary muscles in the left ventricle: prevalence, electrocardiographic and electrophysiological characteristics, and results of the radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2010;21:62–69.

S8.3.14. Bassil G, Liu CF, Markowitz SM, et al. Comparison of robotic magnetic navigation-guided and manual catheter ablation of ventricular arrhythmias arising from the papillary muscles. Europace 2018;20:ii5–ii10.

S8.3.15. Ban JE, Lee HS, Lee DI, et al. Electrophysiological characteristics related to outcome after catheter ablation of idiopathic ventricular arrhythmia originating from the papillary muscle in the left ventricle. Korean Circ J 2013; 43:811–818.

S8.3.16. Crawford T, Mueller G, Good E, et al. Ventricular arrhythmias originating from papillary muscles in the right ventricle. Heart Rhythm 2010; 7:725–730.

S8.3.17. Rivera S, Ricapito Mde L, Tomas L, et al. Results of cryoenergy and radiofrequency-based catheter ablation for treating ventricular arrhythmias arising from the papillary muscles of the left ventricle, guided by intracardiac echocardiography and image integration. Circ Arrhythm Electrophysiol 2016;9:e003874.

S8.3.18. Proietti R, Rivera S, Dussault C, et al. Intracardiac echo-facilitated 3D electroanatomical mapping of ventricular arrhythmias from the papillary muscles: assessing the 'fourth dimension' during ablation. Europace 2017; 19:21–28.

S8.3.19. Peichl P, Baran J, Wichterle D, et al. The tip of the muscle is a dominant location of ventricular ectopy originating from papillary muscles in the left ventricle. J Cardiovasc Electrophysiol 2018;29:64–70.

S8.3.20. Lee A, Hamilton-Craig C, Denman R, Haqqani HM. Catheter ablation of papillary muscle arrhythmias: implications of mitral valve prolapse and systolic dysfunction. Pacing Clin Electrophysiol 2018;41:750–758.

S8.3.21. Ren JF, Marchlinski FE. Early detection of iatrogenic pericardial effusion: importance of intracardiac echocardiography. JACC Cardiovasc Interv 2010;3:127.

S8.3.22. Filgueiras-Rama D, de Torres-Alba F, Castrejón-Castrejón S, et al. Utility of intracardiac echocardiography for catheter ablation of complex cardiac arrhythmias in a medium-volume training center. Echocardiography 2015; 32:660–670.

S8.3.23. Weintraub AR, Schwartz SL, Smith J, Hsu TL, Pandian NG. Intracardiac two-dimensional echocardiography in patients with pericardial effusion and cardiac tamponade. J Am Soc Echocardiogr 1991;4:571–576.

S8.3.24. Bala R, Ren JF, Hutchinson MD, et al. Assessing epicardial substrate using intracardiac echocardiography during VT ablation. Circ Arrhythm Electrophysiol 2011;4:667–673.

S8.3.25. Peichl P, Wichterle D, Cihak R, Aldhoon B, Kautzner J. Catheter ablation of ventricular tachycardia in the presence of an old endocavitary thrombus guided by intracardiac echocardiography. Pacing Clin Electrophysiol 2016;39:581–587.

8.4. Electroanatomical Mapping Systems and Robotic Navigation

Recommendations for the use of EAM systems and remote navigation in ablation procedures for VAs

COR	LOE	Recommendations	References
I	B-NR	**1. In patients with VA due to SHD undergoing an ablation procedure, EAM is useful.**	S8.4.1–S8.4.9
IIa	B-NR	**2. In patients with idiopathic VA undergoing an ablation procedure, EAM can be useful.**	S8.4.4,S8.4.6
IIa	B-NR	**3. In patients undergoing an ablation procedure for VA, magnetic catheter navigation can be useful to reduce fluoroscopy use.**	S8.4.10–S8.4.14

References

S8.4.1. Khaykin Y, Skanes A, Whaley B, et al. Real-time integration of 2D intracardiac echocardiography and 3D electroanatomical mapping to guide ventricular tachycardia ablation. Heart Rhythm 2008;5:1396–1402.

S8.4.2. Sporton SC, Earley MJ, Nathan AW, Schilling RJ. Electroanatomic versus fluoroscopic mapping for catheter ablation procedures: a prospective randomized study. J Cardiovasc Electrophysiol 2004;15:310–315.

S8.4.3. Earley MJ, Showkathali R, Alzetani M, et al. Radiofrequency ablation of arrhythmias guided by non-fluoroscopic catheter location: a prospective randomized trial. Eur Heart J 2006;27:1223–1229.

S8.4.4. Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation 2000;101:1288–1296.

S8.4.5. Khongphatthanayothin A, Kosar E, Nademanee K. Nonfluoroscopic three-dimensional mapping for arrhythmia ablation: tool or toy? J Cardiovasc Electrophysiol 2000;11:239–243.

S8.4.6. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008;118:2773–2782.

S8.4.7. Reithmann C, Hahnefeld A, Remp T, et al. Electroanatomic mapping of endocardial right ventricular activation as a guide for catheter ablation in patients with arrhythmogenic right ventricular dysplasia. Pacing Clin Electrophysiol 2003;26:1308–1316.
S8.4.8. Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease. Circulation 2007; 116:2241–2252.
S8.4.9. Codreanu A, Odille F, Aliot E, et al. Electroanatomic characterization of post-infarct scars comparison with 3-dimensional myocardial scar reconstruction based on magnetic resonance imaging. J Am Coll Cardiol 2008; 52:839–842.
S8.4.10. Zhang F, Yang B, Chen H, et al. Magnetic versus manual catheter navigation for mapping and ablation of right ventricular outflow tract ventricular arrhythmias: a randomized controlled study. Heart Rhythm 2013; 10:1178–1183.
S8.4.11. Dinov B, Schoenbauer R, Wojdyla-Horodynska A, et al. Long-term efficacy of single procedure remote magnetic catheter navigation for ablation of ischemic ventricular tachycardia: a retrospective study. J Cardiovasc Electrophysiol 2012;23:499–505.
S8.4.12. Szili-Torok T, Schwagten B, Akca F, et al. Catheter ablation of ventricular tachycardias using remote magnetic navigation: a consecutive case-control study. J Cardiovasc Electrophysiol 2012;23:948–954.
S8.4.13. Akca F, Theuns DA, Abkenari LD, de Groot NM, Jordaens L, Szili-Torok T. Outcomes of repeat catheter ablation using magnetic navigation or conventional ablation. Europace 2013;15:1426–1431.
S8.4.14. Bauernfeind T, Akca F, Schwagten B, et al. The magnetic navigation system allows safety and high efficacy for ablation of arrhythmias. Europace 2011; 13:1015–1021.

Section 9 Mapping and Ablation

This section is designed as a "how-to" section that details the procedural steps of VT ablation in different patient populations ranging from ablation of PVCs in patients without heart disease to ablation of VT/VF in patients with different types of SHD (Figures 7–12 and Tables 5–8). Bullet points summarize the key points in this section.

9.1. Ablation Power Sources and Techniques

Key Points

- An impedance drop $\geq$10 ohms or a contact force $\geq$10 g is commonly used as a target for radiofrequency energy delivery.
- The use of half normal saline generates larger ablation lesions but can result in steam pops.
- Simultaneous bipolar or unipolar ablation can result in larger ablation lesions.
- Cryoablation can be beneficial for achieving more stable contact on the papillary muscles.
- Ethanol ablation can generate lesions in areas where the arrhythmogenic substrate cannot be otherwise reached, provided that suitable target vessels are present.
- Stereotactic radiotherapy is an emerging alternative to ablation, requiring identification of a region of interest that can be targeted prior to the radiation treatment.

9.2. Idiopathic Outflow Tract Ventricular Arrhythmia

Key Points

- The RVOT, pulmonary arteries, SVs, LV epicardium and endocardium contain most of the outflow tract arrhythmias.
- Activation mapping and pace mapping can be used to guide ablation in the RVOT.
- Imaging of coronary artery ostia is essential before ablation in the aortic SVs.
- The LV summit is a challenging site of origin, often requiring mapping and/or ablation from the RVOT, LVOT, SVs, coronary venous system, and sometimes the epicardial space.
- Deep intraseptal VA origins can be challenging to reach.




Figure 7 Anatomical boundaries of the LV summit, with the inaccessible [1] and accessible [2] parts. Shown are the left anterior descending artery (LAD), the circumflex artery (Cx), the great cardiac vein (GCV), the anterior interventricular vein (AIV), and the first and second diagonal branch of the LAD (D1, D2).

9.3. Idiopathic Nonoutflow Tract Ventricular Arrhythmia

Key Points

- VAs originating from the papillary muscles can be challenging due to multiple morphologies of the VA and the difficulty in achieving and maintaining sufficient contact during ablation.
- VAs originate in LV papillary muscles more often than in RV papillary muscles; they more often originate from the posteromedial than the anterolateral papillary muscle and occur more often at the tip than at the base.
- Pace mapping is less accurate than in other focal VAs.
- ICE is particularly useful for assessing contact and stability.
- Cryoablation can also aid in catheter stability during lesion delivery.




Figure 8 Intraprocedural imaging during ablation of papillary muscle arrhythmias. (A): Anatomical map of the left ventricle (CARTO, Biosense Webster) showing contact of the ablation catheter (Abl) with the posteromedial papillary muscle (PMPAP). (B): Intracardiac echocardiogram showing real-time visualization of the ablation catheter during ablation on the anterolateral papillary muscle (ALPAP).

9.4. Bundle Branch Reentrant Ventricular Tachycardia and Fascicular Ventricular Tachycardia

Key Points

- Bundle branch reentry can occur in a variety of patients in whom the conduction system can be affected, including patients with dilated cardiomyopathy (DCM), valvular heart disease, myocardial infarction, myotonic dystrophy, Brugada syndrome, and ARVC, among others.
- Ablation of either the right or left bundle branch eliminates bundle branch reentrant ventricular tachycardia (BBRVT) but does not eliminate other arrhythmic substrates.
- A correct diagnosis of BBRVT is crucial and should employ established criteria prior to ablation of either of the bundle branches.
- Ablation of the AV node does not cure BBRVT.
- Ablation of either bundle branch does not cure interfascicular VT.
- For posterior fascicular VTs, the P1 potential is targeted during VT; if P1 cannot be identified or VT is not tolerated, an anatomical approach can be used.
- Purkinje fibers can extend to the papillary muscles, and these can be part of the VT circuit.
- For anterior fascicular VTs, the P1 potential is targeted with ablation.
- Focal nonreentrant fascicular VT is infrequent and can occur in patients with IHD; however, it cannot be induced with programmed stimulation, and the target is the earliest Purkinje potential during VT.

Table 5 Types of bundle branch reentrant tachycardia

	Type A	Type B (Interfascicular tachycardia)	Type C
ECG morphology	LBBB pattern	RBBB pattern	RBBB pattern
Anterograde limb	RBB	LAF or LPF	LBB
Retrograde limb	LBB	LPF or LAF	RBB

LAF = left anterior fascicle; LBB = left bundle branch; LBBB = left bundle branch block; LPF = left posterior fascicle; RBB = right bundle branch; RBBB = right bundle branch block.

Table 6 Fascicular ventricular tachycardias

I. Verapamil-sensitive fascicular reentrant VT
- **1. Left posterior type**
  - i. Left posterior septal fascicular reentrant VT
  - ii. Left posterior papillary muscle fascicular reentrant VT
- **2. Left anterior type**
  - i. Left anterior septal fascicular reentrant VT
  - ii. Left anterior papillary muscle fascicular reentrant VT
- **3. Upper septal type**

II. Nonreentrant fascicular VT

VT = ventricular tachycardia.

9.5. Postinfarction Ventricular Tachycardia

Key Points

- In cases of multiple inducible VTs, the clinical VT should be preferentially targeted.
- Elimination of all inducible VTs reduces VT recurrence and is associated with prolonged arrhythmia-free survival.
- For tolerated VTs, entrainment mapping allows for focal ablation of the critical isthmus.
- For nontolerated VTs, various ablation strategies have been described, including targeting abnormal potentials, matching pace mapping sites, areas of slow conduction, linear lesions, and scar homogenization.
- Imaging can be beneficial in identifying the arrhythmogenic substrate.
- Epicardial ablation is infrequently required, but epicardial substrate is an important reason for VT recurrence after VT ablation in patients with prior infarcts.




Figure 9 Overview of the workflow for catheter ablation of VT in patients with IHD. Not all of these steps might be required, and steps can be performed in a different sequence. For instance, repeat VT induction can be deferred in patients with hemodynamic instability. In addition, the operator might have to adapt to events that arise during the case, for instance, to take advantage of spontaneous initiation of stable VT during substrate mapping and switch to activation mapping. IHD = ischemic heart disease; PES = programmed electrical stimulation; SR = sinus rhythm; VT = ventricular tachycardia.

Table 7 Select recent radiofrequency catheter ablation studies in patients post myocardial infarction with a focus on substrate-based ablation strategies

Study	N	EF (%)	Prior CABG (%)	Inclusion	Access mapping catheter	Mapping strategy	Ablation strategy	Procedural endpoint	RF time procedural duration complications	VT recurrence and burden (follow-up)
Jais et al. (2012) (S9.5.1) Two centers observational	70	35 ± 10	NR	1) Sustained VT resistant to AAD therapy and requiring external cardioversion or ICD therapies 2) SHD with ischemic or nonischemic dilated cardiomyopathy Exclusions: 1) VA attributable to an acute or reversible cause 2) Repetitive PVCs or nonsustained VT without sustained VT	Retrograde in 61 pts (87%) Transseptal in 32 pts (46%); epicardial access in 21 pts (31%) Dual access encouraged 3.5-mm external irrigated ablation catheter; multielectrode mapping catheter in 50% endocardial procedures and in all epicardial procedures	1) PES and activation mapping of induced stable VTs 2) Substrate mapping for LAVAs — sharp high-frequency electrograms often of low amplitude, occurring during or after the far-field ventricular electrogram, sometimes fractionated or multicomponent, poorly coupled to the rest of the myocardium	1) Ablation of LAVA in SR 2) Ablation of tolerated VTs guided by entrainment and activation mapping 3) Remapping (in stable patients) with further ablation if residual LAVA or persistent inducibility	1) Complete LAVA elimination — achieved in 47 of 67 pts with LAVA (70.1%) 2) Noninducibility — achieved in 70%, similar if LAVA eliminated or not	RF time 23 ± 11 min Procedure time 148 ± 73 min Complications 6 pts (8.6%): tamponade or bleeding managed conservatively (3), RV perforation requiring surgical repair (1); 3 pts died within 24 h due to low-flow state (2) plus arrhythmia recurrence (1), PEA (1)	Combined endpoint of VT recurrence or death occurred in 39 pts (55.7%); 45% of pts with LAVA elimination and 80% of those without VT recurrence in 32 (46%); 32% of pts with LAVA elimination and 75% of those without 7 cardiac deaths (10%) over 22 months of median follow-up
Di Biase et al. (2015) (S9.5.2) VISTA trial Multicenter RCT	118	Group 1 33 ± 14 Group 2 32 ± 10	34%	1) Post-MI 2) Recurrent stable AAD refractory VT (symptomatic or requiring ICD therapy) Exclusion: syncope, cardiac arrest, prior failed ablation, renal failure, end-stage heart failure	Endocardial Epicardial when clinical VTs were inducible after endocardial ablation + no CABG Group 1: 11.7% Group 2: 10.3% 3.5-mm tip	1) Substrate mapping (BV ≤1.5 mV) + Group 1 2) PES and activation mapping/pace mapping for clinical and stable nonclinical VT (unstable VT not targeted)	Group 1: Clinical VT ablation, linear lesion to transect VT isthmus Group 2: Extensive substrate ablation targeting any abnormal potential (=fractionated and/or LP)	Group 1: Noninducibility of clinical VT — achieved in 100% Group 2: 1) Elimination of abnormal potentials 2) No capture from within the scar (20 mA) 3) Noninducibility of clinical VT — achieved in 100%	Group 1: RF time 35 ± 27 min Procedural time 4.6 ± 1.6 h Group 2: RF time 68 ± 27 min ($P <$ .001) Procedural time 24.2 ± 1.3 h (P = .13) Complications 5%	VT recurrence at 12 months Group 1: 48.3% Group 2: 15.5% $P <$ .001 Mortality at 12 months Group 1: 15% Group 2: 8.6% P = .21
Tilz et al. (2014) (S9.5.3) Single center observational	12 12/117 pts with post-MI VT	32 ± 13	—	1) Presence of a circumscribed dense scar (BV <1.5 mV, area <100 cm^2) 2) Recurrent unmappable VT 3) Post-MI Exclusion: patchy scar/multiple scars	Endocardial 3.5-mm tip	1) PES 2) Substrate mapping: area of BV <1.5 mV + double, fractionated or LP 3) PES after ablation	Circumferential linear lesion along BZ (BV <1.5 mV) to isolate substrate	1) Lack of abnormal EGMs within area 2) No capture within area — achieved in 50% 3) Max. 40 RF lesion Noninducibility of any VT (no predefined endpoint) —observed in 92%	RF time 53 ± 15 min Procedure time 195 ± 64 min No complication	VT recurrence 33% Median follow-up 497 days
Tzou et al. (2015) (S9.5.4) Two centers observational	44 Post-MI 32 44/566 pts with SHD	31 ± 13	—	1) SHD 2) AAD refractory VT 3) Intention to achieve core isolation	Endocardial Epicardial post-MI 6% 3.5-mm tip Selected patients: multi-electrode catheters for exit block evaluation	1) BV mapping 2) PES 3) Activation mapping 4) Substrate mapping Dense scar BV <0.5 mV; BZ BV 0.5–1.5 mV/voltage channels/ fractionated/LP; pace-match, S-QRS >40 ms 5) PES after core isolation	1) Circumferential linear lesion to isolate core (=confluent area of BV <0.5 mV area and regions with BV <1 mV harbouring VT-related sites 2) Targeting fractionated and LP within core 3) Targeting VT-related sites outside core (2 and 3 in 59%)	1) No capture of the ventricle during pacing inside core 2) Dissociation of isolated potentials — core isolation achieved in 70% post-MI 3) Noninducibility — achieved in 84%	RF lesions 111 ± 91 Procedure time 326 ± 121 min Complications 2.2% No death	VT recurrence 14% Follow-up 17.5 ± 9 months

(*Continued*)

Table 7 (*Continued*)

Study	N	EF (%)	Prior CABG (%)	Inclusion	Access mapping catheter	Mapping strategy	Ablation strategy	Procedural endpoint	RF time procedural duration complications	VT recurrence and burden (follow-up)
Silberbauer et al. (2014) (S9.5.5) One center observational	160	28 ± 9.5 inducible after RFCA 34 ± 9.2 endpoint reached	22.5%	1) Post-MI 2) AAD refractory VT 3) First VT ablation at the center	Endocardial Combined endoepicardial (20%) — Clinical findings — Prior ablation — Research protocol 3.5-mm tip/4-mm tip	1) Substrate mapping: BV <1.5 mV + LP (=continuous, fragmented bridging to components after QRS offset/ inscribing after QRS, no voltage cutoff) + early potentials (EP = fragmented <1.5 mV) Pace-match 2) PES 3) Activation mapping 4) PES after substrate ablation	1) Ablation mappable VT 2) Ablation of all LP LP present at baseline Endocardium 100/160 pts Epicardium 19/32 pts	1) Abolition of all LP — achieved at endocardium in 79 pts (49%), at epicardium 12/32 pts (37%) 2) Noninducibility of any VT — achieved in 88%	RF time endocardial median ≈25 min epicardial ≈6 min Procedure time Median 210–270 min Complications 3.1% In-hospital mortality 2.5%	VT recurrence 32% after median 82 (16–192) days VT recurrence according to endpoint 1+2 achieved (16.4%) Endpoint 2 achieved (46%) No endpoint achieved (47.4%)
Wolf et al. (2018) (S9.5.6) One center observational	159	34 ± 11	25%	1) Post-MI 2) First VT ablation 3) Recurrent, AAD refractory episodes VT	Endocardial Combined endoepicardial 27% — Epicardial access was encouraged — Epicardial ablation 27/46 pts 3.5-mm tip (70 pts) Multielectrode catheters (89 pts)	1) PES 2) Activation mapping 3) Substrate mapping: BV mapping (<1.5 mV) + LAVA (=sharp high-frequency EGMs, possibly of low amplitude, distinct from the far-field EGM occurring anytime during or after the far-field EGM 4) PES	1) Ablation of mappable VT 2) Ablation of LAVA (until local no capture) LAVA present at baseline Endocardium 141/157 pts Epicardium 36/46 pts	1) Abolition of LAVA — achieved in 93/146 pts (64%) 2) Noninducibility — achieved in 94/110 tested pts	RF time 36 ± 20 min Procedure time 250 ± 78 min Complications 7.5% (4 surgical interventions) Procedure-related mortality 1.3%	VT-free survival 55% during 47 months (33–82) Outcome according to endpoints: LAVA abolished vs not abolished 63% vs 44% VT-free survival at 1 year 73%
Berruezo et al. (2015) (S9.5.7) One center observational	101 Post-MI 75	36 ± 13	—	1) Scar-related VT	Endocardial Combined endoepicardial (27/101 pts, among post-MI not provided) — Endo no substrate/ suggestive epi — CE-MRI — VT ECG 3.5-mm tip	1) Substrate mapping: BV (<1.5 mV) + EGMs with delayed components: identification of entrance (shortest delay) of conducting channels 2) PES 3) Activation mapping + pace-match	1) Scar dechanneling targeting entrance 2) Short linear lesions (eg, between scar and mitral annulus) 3) Ablation of VT-related sites — performed in 45%	1) Scar dechanneling — Achieved in 85 pts (84.2%) — Noninducible after 1) 55 pts (54.5%) 2) Noninducibility —achieved in 78%	RF time 24 ± 10 min only scar dechanneling (31 ± 18 min + additional RFCA) Procedure time 227 ± 69 min Complications 6.9% No death	VT recurrence 27% after a median follow-up of 21 months (11–29) 1-year VT-free survival according to endpoint: scar dechanneling complete vs incomplete (≈82% vs ≈65%)

(*Continued*)

Porta-Sánchez et al. (2018) (S9.5.8) Multicenter observational	20	33 ± 11	—	1) Post-MI 2) Recurrent VT	Endocardial 3.5-mm tip 4 pts Multielectrode catheters 16 pts	1) Substrate mapping: annotation of LP (=fractionated/isolated after QRS offset) and assessment if LP showed additional delay of >10 ms after RV extrastimuli (S1 600 ms, S2 VERP + 20 ms) defined as DEEP 2) PES 3) Additional mapping	1) Targeting areas with DEEP 2) Ablation of VT-related sites discretion of operator	1) Noninducibility—achieved in 80% after DEEP ablation — Remains 80% after additional ablation in those inducible	RF time 30.6 ± 21.4 min Procedure time and complications not reported	VT recurrence 25% at 6-month follow-up
de Riva et al. (2018) (S9.5.9) One center observational	60	33 ± 12	30%	1) Post-MI 2) Sustained VT	Endocardial Epicardial 10% — Endocardial failure — Epicardial substrate suspected 3.5-mm tip catheter	1) PES 2) Substrate mapping: systematic assessment of presumed infarct area independent of BV during SR and RV extrastimuli Pacing (S1 500 ms, S2 VRP + 50ms): EDP (evoked delayed potentials) = low voltage (<1.5 mV) EGM with conduction delay >10 ms or block in response to S2 3) Activation and pace mapping	1) Targeting EDPs only 2) Ablation of VT-related sites based on activation/pace mapping	1) Elimination of EDPs — achieved in all 2) Noninducibility of targeted VT (fast VT with VTCL ≈ VERP not targeted) — Achieved in 67% after EDP ablation — Achieved in 90% after additional ablation	RF time 15 min (10–21) Procedure time 173 min (150–205) Complications 3.3% One procedure-related death	VT recurrence 22% at median follow-up of 16 months (8–23) Subgroup of patients with EDPs in normal-voltage areas at baseline (hidden substrate) compared to historical matched group without EDP mapping VT-free survival at 1 year 89% vs 73%

Included studies: post myocardial infarction (or data for patients post myocardial infarction provided).

AAD = antiarrhythmic drug; BV = bipolar voltage; BZ = border zone; CABG = coronary artery bypass grafting; CE-MRI = contrast-enhanced magnetic resonance imaging; DC = delayed component; DEEP = decremental evoked potential; ECG = electrocardiogram; EDP = evoked delayed potential; EF = ejection fraction; EGM = electrogram; ICD = implantable cardioverter defibrillator; LAVA = local abnormal ventricular activity; MI = myocardial infarction; PEA = pulseless electrical activity; PES = programmed electrical stimulation; pts = patients; PVC = premature ventricular complex; RCT = randomized controlled trial; RF = radiofrequency; RFCA = radiofrequency catheter ablation; RV = right ventricle; SHD = structural heart disease; SR = sinus rhythm; VT = ventricular tachycardia.

References

S9.5.1. Jais P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia. Circulation 2012;125:2184–2196.

S9.5.2. Di Biase L, Burkhardt JD, Lakkireddy D, et al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy: the VISTA randomized multicenter trial. J Am Coll Cardiol 2015;66:2872–2882.

S9.5.3. Tilz RR, Makimoto H, Lin T, et al. Electrical isolation of a substrate after myocardial infarction: a novel ablation strategy for unmappable ventricular tachycardias–feasibility and clinical outcome. Europace 2014;16:1040–1052.

S9.5.4. Tzou WS, Frankel DS, Hegeman T, et al. Core isolation of critical arrhythmia elements for treatment of multiple scar-based ventricular tachycardias. Circ Arrhythm Electrophysiol 2015;8:353–361.

S9.5.5. Silberbauer J, Oloriz T, Maccabelli G, et al. Noninducibility and late potential abolition: a novel combined prognostic procedural end point for catheter ablation of postinfarction ventricular tachycardia. Circ Arrhythm Electrophysiol 2014;7:424–435.

S9.5.6. Wolf M, Sacher F, Cochet H, et al. Long-term outcome of substrate modification in ablation of post-myocardial infarction ventricular tachycardia. Circ Arrhythm Electrophysiol 2018;11:e005635.

S9.5.7. Berruezo A, Fernandez-Armenta J, Andreu D, et al. Scar dechanneling: new method for scar-related left ventricular tachycardia substrate ablation. Circ Arrhythm Electrophysiol 2015;8:326–336.

S9.5.8. Porta-Sanchez A, Jackson N, Lukac P, et al. Multicenter study of ischemic ventricular tachycardia ablation with decrement-evoked potential (DEEP) mapping with extra stimulus. JACC Clin Electrophysiol 2018;4:307–315.

S9.5.9. de Riva M, Naruse Y, Ebert M, et al. Targeting the hidden substrate unmasked by right ventricular extrastimulation improves ventricular tachycardia ablation outcome after myocardial infarction. JACC Clin Electrophysiol 2018;4:316–327.

9.6. Dilated Cardiomyopathy

Key Points

- Identifying the location and extent of scarring on CMR is beneficial in procedural planning and has improved the outcomes of ablation in patients with DCM.
- The ablation strategy is similar to postinfarction VT.
- An intramural substrate is more frequently encountered in DCM than in postinfarction patients and requires a different ablation strategy than for patients with either epicardial or endocardial scarring.
- Epicardial ablation is beneficial if the scar is located in the epicardium of the LV free wall.
- For intramural circuits involving the septum, epicardial ablation is not beneficial.
- In the absence of CMR, unipolar voltage mapping has been described as a method to indicate a deeper-seated scar.

9.7. Ventricular Tachycardia Ablation in Hypertrophic Cardiomyopathy

Key Points

- Polymorphic VT and VF are the most common VAs in HCM; monomorphic VT is less common.
- The arrhythmogenic substrate in HCM often involves the septum but can extend to the epicardium, often necessitating combined endocardial and epicardial ablation procedures to eliminate the VT.
- VT associated with apical aneurysms is often ablated endocardially.

9.8. Brugada Syndrome

Key Points

- PVC-triggered VF or polymorphic VT are the most prevalent VAs that motivate device therapy in patients with Brugada syndrome.
- Monomorphic VT is less frequent but can be caused by BBRVT in patients with Brugada syndrome.
- The arrhythmogenic substrate is located in the RV epicardium and can be demonstrated by sodium channel blockers.
- Ablation targets include fractionated prolonged electrograms on the epicardial aspect of the RV.

9.9. Polymorphic Ventricular Tachycardia/ Ventricular Fibrillation Triggers

Key Points

- Recurrent PVC-induced VF is most often triggered by PVCs originating from Purkinje fibers, located in the RVOT, the moderator band, or the LV.
- Patients with a single triggering PVC are better ablation candidates; however, there are often multiple triggers.
- Patients with healed myocardial infarction often require extensive ablation of the Purkinje fiber system within or at the scar border.
- Ischemia should be ruled out as a trigger for VF prior to ablation.




Figure 10 Epicardial substrate ablation in a patient with Brugada syndrome and appropriate ICD shocks for VF. Image integration of a preacquired CT with the electroanatomical epicardial substrate map is shown in (A). Purple represents bipolar voltage >1.5 mV. Fractionated potentials (arrows) are tagged with black dots, and a representative example is displayed. Widespread fractionated potentials were recorded from the epicardial aspect of the RVOT extending down into the basal RV body. Ablation lesions are tagged with red dots. Some fractionated potentials could not be ablated due to the proximity of the acute marginal branches of the right coronary artery. Panel (B) shows the significant transient accentuation of the Brugada ECG pattern during the application of radiofrequency energy at one of these sites. CT = computed tomography; ECG = electrocardiogram; ICD = implantable cardioverter defibrillator; PA = pulmonary artery; RA = right atrium; RCA = right coronary artery; RFA = radiofrequency ablation; RV = right ventricle; RVOT = right ventricular outflow tract; VF = ventricular fibrillation.

9.10. Arrhythmogenic Right Ventricular Cardiomyopathy

Key Points

- The arrhythmogenic substrate in ARVC is located in the epicardium and can involve the endocardium in advanced stages.
- The most commonly affected areas are the subtricuspid and RV outflow regions.
- LV involvement is not uncommon.
- Endocardial-epicardial ablation is often required and results in higher acute success and lower recurrence rates compared with endocardial ablation alone.
- Conventional mapping and ablation techniques, including entrainment mapping of tolerated VT, pace mapping, and substrate ablation, are used.




Figure 11 Right ventricular voltage maps from cases of moderate (upper row) and advanced (lower row) arrhythmogenic right ventricular cardiomyopathy (ARVC) are shown. Purple represents a voltage >1.5 mV in the bipolar maps (left and right) and >5.5 mV in the unipolar maps (center); red represents a voltage <0.5 mV in the bipolar maps and <3.5 mV in the unipolar maps. Moderate ARVC is defined as having a bipolar/unipolar low-voltage area ratio of <0.23 and is associated with epicardial arrhythmogenic substrate area (ASA) (defined by the presence of electrograms with delayed components of >10 cm^2. Advanced ARVC displays a bipolar/unipolar endocardial low-voltage area of ≥0.23, which is associated with an epicardial arrhythmogenic substrate area of ≤10 cm^2. Adapted with permission from Oxford University Press (Berruezo et al. Europace 2017;19:607–616).

9.11. Mapping and Ablation in Congenital Heart Disease

Key Points

- Patients with a VT substrate after congenital heart defect surgery include those with repaired tetralogy of Fallot, repaired ventricular septal defect, and repaired d-transposition of the great arteries (D-TGA), as well as Ebstein's anomaly among other disease processes.
- VT isthmuses are often located between anatomical barriers and surgical incisions or patch material.
- An anatomical isthmus can be identified and targeted during sinus rhythm.
- For tolerated VTs, entrainment mapping is the method of choice for identifying critical components of the reentry circuit.




Figure 12 Anatomical isthmuses (AI) in repaired tetralogy of Fallot according to the surgical approach and variation of the malformation. RV = right ventricular; TA = tricuspid annulus; VSD = ventricular septal defect.

9.12. Sarcoidosis

Key Points

- The arrhythmogenic substrate in cardiac sarcoidosis is often intramurally located but can include the endocardium and epicardium.
- A CMR is beneficial in planning an ablation procedure in cardiac sarcoidosis.
- The arrhythmogenic substrate can be complex and can include areas of active inflammation and chronic scarring.
- The VT recurrence rate after ablation is high.

Table 8 Catheter ablation of ventricular arrhythmias in cardiac sarcoidosis

Study	N	LVEF, %	Concurrent immuno-suppressive therapy, n (%)	VTs induced, mean ± SD	Mapping, Endo n/ Epi n	Ablation, Endo n/ Epi n	Patients undergoing repeated procedures, n (%)	VT Recurrence, n (%)	VT Burden decrease, n (%)	Major complications	Follow-up, months
Koplan et al. (S9.12.5)	8	35 ± 15	5 (63)	4 ± 2	6/2	8/2	1 (13)	6 (75)	4 (44)	NR	6
Jefic et al. (S9.12.2)	9	42 ± 14	8 (89)	5 ± 7	8/1	NR	3 (33)	4 (44)	9 (100)	NR	20
Naruse et al. (S9.12.3)	14	40 ± 12	12 (86)	3 ± 1	14/0	14/0	4 (29)	6 (43)	NR	NR	33
Dechering et al. (S9.12.1)	8	36 ± 19	NR	4 ± 2	NR	NR	NR	1 (13)	7 (88)	NR	6
Kumar et al. (S9.12.6)	21	36 ± 14	12 (57)	Median 3 (range 1–8)	21/8	21/5	11 (52)	15 (71)	16 (76)	4.7%	24
Muser et al. (S9.12.4)	31	42 ± 15	22 (71)	Median 3 (range 1–5)	31/11	31/8	9 (29)	16 (52)	28 (90)	4.5%	30

LVEF = left ventricular ejection fraction; N = number; NR = not reported; VT = ventricular tachycardia.

References

S9.12.1. Dechering DG, Kochhaüser S, Wasmer K, et al. Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2013; 10:158–164.

S9.12.2. Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 2009;6:189–195.

S9.12.3. Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2014;7:407–413.

S9.12.4. Muser D, Santangeli P, Pathak RK, et al. Long-term outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2016;9:e004333.

S9.12.5. Koplan BA, Soejima K, Baughman KL, Epstein LM, Stevenson WG. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm 2006; 3:924–929.

S9.12.6. Kumar S, Barbhaiya C, Nagashima K, et al. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015; 8:87–93.

9.13. Chagas Disease

Key Points

- The pathogenesis of Chagas disease is poorly understood but often results in an inferolateral LV aneurysm.
- The arrhythmogenic substrate is located intramurally and on the epicardial surface, often necessitating an epicardial ablation procedure.

9.14. Miscellaneous Diseases and Clinical Scenarios With Ventricular Tachycardia

Key Points

- Lamin cardiomyopathy often has a poor prognosis, progressing to end-stage heart failure.
- VT ablation is challenging due to intramural substrates.
- VT recurrence rate is high after ablations.
- VT in patients with noncompaction tends to originate from regions of noncompacted myocardium where scar can be identified in the midapical LV.
- VT ablation in patients with LV assist device can be challenging due to the limitation of preprocedural imaging, and the electromagnetic noise generated by the LV assist device.

9.15. Surgical Therapy

Key Points

- Surgery-facilitated access to the epicardium via a limited subxiphoid incision can be helpful in the case of adhesions.
- Cryoablation via thoracotomy is possible for posterolateral substrates and via sternotomy for anterior substrates.

9.16. Sympathetic Modulation

Key Points

- Sympathetic modulation targeting the stellate ganglia by video-assisted thoracoscopy may be considered for failed VT ablation procedures or VF storms.
- A temporary effect can be obtained with the percutaneous injection or infusion of local anesthetics.

9.17. Endpoints of Catheter Ablation of Ventricular Tachycardia

Key Points

- Noninducibility of VT by PES after ablation is a reasonable endpoint and predictor for VT recurrence after VT ablation in patients with SHD.
- Due to the limitations of programmed stimulation, endpoints other than noninducibility have been described, including elimination of excitability, elimination of late potentials or local abnormal ventricular activity, dechanneling, substrate homogenization, core isolation, image-guided ablation, and anatomically fixed substrate ablation.

Section 10 Postprocedural Care

Access-related issues, anticoagulation (Table 9), and complications (Table 10), as well as the management thereof, are reviewed in this section. Furthermore, assessment of outcomes and determinants of outcomes are detailed (Figure 13).

10.1. Postprocedural Care: Access, Anticoagulation, Disposition

10.1.1. Postprocedural Care: Access

Recommendations for management of venous access sites after catheter ablation of VA

COR	LOE	Recommendations	References
I	A	1. Manual compression is effective in achieving hemostasis after venous access for VT ablation.	S10.1.1.1–S10.1.1.3
IIa	B-R	2. Venous access closure using temporary purse-string or figure-of-8 suture techniques can be useful in achieving faster hemostasis and earlier ambulation and reducing pain or discomfort associated with hemostasis compared to manual compression.	S10.1.1.1,S10.1.1.2

Recommendation for management of arterial access sites after catheter ablation of VA

COR	LOE	Recommendation	References
I	A	1. Achieving arterial access site hemostasis using either manual compression or a vascular closure device is recommended.	S10.1.1.4,S10.1.1.5

Recommendations for management of epicardial access sites after catheter ablation of VA

COR	LOE	Recommendations	References
I	C-EO	1. If pericardial bleeding or cardiac tamponade has occurred during epicardial VT ablation, a pericardial drain should be left in place until bleeding has resolved.	
IIa	B-NR	2. The instillation of intrapericardial corticosteroids can be effective in reducing pericarditic chest pain after epicardial VT mapping or ablation.	S10.1.1.6,S10.1.1.7
IIa	B-NR	3. To reduce pericardial pain after epicardial VT ablation, unless pericardial bleeding or cardiac tamponade has occurred, it is reasonable to remove all pericardial access sheaths at the end of the procedure.	S10.1.1.6,S10.1.1.7
IIb	C-EO	4. Leaving a pericardial drain in place might be reasonable in patients at high risk for late bleeding or cardiac tamponade after epicardial VT ablation.	

References

S10.1.1.1. Jackson N, McGee M, Ahmed W, et al. Groin haemostasis with a purse string suture for patients following catheter ablation procedures (GITAR study). Heart Lung Circ 2018 March 20; https://doi.org/10.1016/j.hlc.2018.03.011 [Epub ahead of print].

S10.1.1.2. Pracon R, Bangalore S, Henzel J, et al. A randomized comparison of modified subcutaneous "Z"-stitch versus manual compression to achieve hemostasis after large caliber femoral venous sheath removal. Catheter Cardiovasc Interv 2018;91:105–112.

S10.1.1.3. Ben-Dor I, Craig P, Torguson R, et al. MynxGrip vascular closure device versus manual compression for hemostasis of percutaneous transfemoral venous access closure: results from a prospective multicenter randomized study. Cardiovasc Revasc Med 2018;19:418–422.

S10.1.1.4. Robertson L, Andras A, Colgan F, Jackson R. Vascular closure devices for femoral arterial puncture site haemostasis. Cochrane Database Syst Rev 2016;3:CD009541.

S10.1.1.5. Jiang J, Zou J, Ma H, et al. Network meta-analysis of randomized trials on the safety of vascular closure devices for femoral arterial puncture site haemostasis. Sci Rep 2015;5:13761.

S10.1.1.6. Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia: a European multicenter study. Circ Arrhythm Electrophysiol 2011;4:653–659.

S10.1.1.7. Dyrda K, Piers SR, van Huls van Taxis CF, Schalij MJ, Zeppenfeld K. Influence of steroid therapy on the incidence of pericarditis and atrial fibrillation after percutaneous epicardial mapping and ablation for ventricular tachycardia. Circ Arrhythm Electrophysiol 2014;7:671–676.

10.1.2. Postprocedural Care: Anticoagulation

Recommendations for anticoagulation after VA ablation procedures

COR	LOE	Recommendations	References
IIa	C-LD	1. After less extensive endocardial VT ablation, treatment with an antiplatelet agent for a limited period of time is reasonable.	S10.1.2.1,S10.1.2.2
IIa	C-LD	2. Heparin reversal with protamine for sheath removal after ablation is reasonable.	S10.1.2.3,S10.1.2.4
IIb	C-LD	3. After extensive endocardial VT ablation, treatment with an oral anticoagulant for a limited period of time might be reasonable.	S10.1.2.1,S10.1.2.2
IIb	C-EO	4. The use of heparin bridging after endocardial VT ablation may be considered but can be associated with an increased risk of periprocedural bleeding.	

Table 9 Postprocedural care in prospective studies of ventricular tachycardia catheter ablation

Study	Postprocedure NIPS	AAD type	AAD duration	Follow-up	ICD programming	Anticoagulation postablation	Bleeding and thromboembolic events (ablation arm)
Calkins 2000 (S10.1.2.5)	No	Patients were continued on the type of antiarrhythmic therapy they had received before ablation.	At least the first 3 months after hospital discharge	Evaluation at 1, 3, 6, 9, 12, and 24 months after ablation	Not specified	Not specified	Four of 146 (2.7%) stroke or TIA, 4 (2.7%) episodes of pericardial tamponade
SMASH-VT 2007 (S10.1.2.6)	No	No patient received an AAD (other than beta blockers) before the primary endpoint was reached.	N/A	Followed in the ICD clinic at 3, 6, 9, 12, 18, and 24 months; echocardiography at 3 and 12 months	Not specified	Oral anticoagulation 4–6 weeks, aspirin if fewer than 5 ablation lesions	One pericardial effusion without tamponade, managed conservatively; 1 deep venous thrombosis
Stevenson 2008 (S10.1.2.1)	No	The previously ineffective AAD was continued for the first 6 months, after which time drug therapy was left to the discretion of the investigator.	Six months, after which time drug therapy was left to the discretion of the investigator	Echocardiogram and neurologist examination before and after ablation; office visit at 2 and 6 months, with ICD interrogation where applicable	Not specified	Three months with either 325 mg/day aspirin or warfarin if ablation had been performed over an area over 3 cm in length	Vascular access complications in 4.7%; no thromboembolic complications
Euro-VT 2010 (S10.1.2.7)	No	Drug management during follow-up was at the discretion of the investigator.	Drug management during follow-up was at the discretion of the investigator.	At 2, 6, and 12 months, with ICD interrogation where applicable	Investigators were encouraged to program ICD detection for slow VT for at least 20 beats or 10 seconds to allow nonsustained VT to terminate before therapy is triggered.	Not specified	No major bleeding or thromboembolic complications
VTACH 2010 (S10.1.2.8)	No	Discouraged	Discouraged	Every 3 months from ICD implantation until completion of the study	VF zone with a cutoff rate of 200–220 bpm and a VT zone with a cutoff CL of 60 ms above the slowest documented VT and ATP followed by shock	Not specified	One transient ischemic ST-segment elevation; 1 TIA

(*Continued*)

Table 9 (*Continued*)

Study	Postprocedure NIPS	AAD type	AAD duration	Follow-up	ICD programming	Anticoagulation postablation	Bleeding and thromboembolic events (ablation arm)
CALYPSO 2015 (S10.1.2.9)	No	Discouraged	Discouraged	At 3 and 6 months	Investigators were required to ensure that VT detection in the ICD is programmed at least 10 beats below the rate of the slowest documented VT.	At the discretion of the treating physician, anticoagulation recommended with aspirin or warfarin for 6–12 weeks	
Marchlinski 2016 (S10.1.2.10)	Not required	Not dictated by the study protocol	Not dictated by the study protocol	At 6 months and at 1, 2, and 3 years	Not dictated by the study protocol	Per clinical conditions and physician preference	Cardiac perforation (n = 1), pericardial effusion (n = 3)
VANISH 2016 (S10.1.2.11)	No	Continued preprocedure antiarrhythmic medications	Not specified	A 3-month office visit, echo, ICD check; a 6-month office visit, ICD check; every 6 months thereafter, an office visit, ICD check	VT detection at 150 bpm or with a 10–20 bpm margin if the patient was known to have a slower VT. ATP was recommended in all zones. The protocol was modified to recommend prolonged arrhythmia detection duration for all patients.	Intravenous heparin (without bolus) 6 hours after sheath removal, then warfarin if substrate-mapping approach used or if more than 10 minutes of RF time	Major bleeding in 3 patients; vascular injury in 3 patients; cardiac perforation in 2 patients
SMS 2017 (S10.1.2.12)	No	At the discretion of the investigator	At the discretion of the investigator	At 3, 6, 9, and 12 months, and at 3- or 6-month intervals until completion of the study or until 33-month follow-up was reached	VF zone at 200–220 bpm, detection 18 of 24 beats, shock only; VT zone detection at least 16 consecutive beats, ATP, and shocks. Where VT rates were exclusively >220 bpm, VT zone at 160–180 bpm was recommended; where VT rates were <220 bpm, VT zone with a CL 60 ms above the slowest VT was recommended	Aspirin (250 mg/day) or warfarin as necessitated by the underlying heart disease	Two tamponades requiring pericardiocentesis

AAD = antiarrhythmic dug; ATP = antitachycardia pacing; CL = cycle length; ICD = implantable cardioverter defibrillator; NIPS = noninvasive programmed stimulation; RF = radiofrequency; TIA = transient ischemic attack; VF = ventricular fibrillation; VT = ventricular tachycardia.

References

S10.1.2.1. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter Thermocool ventricular tachycardia ablation trial. Circulation 2008;118:2773–2782.

S10.1.2.2. Siontis KC, Jame S, Sharaf Dabbagh G, et al. Thromboembolic prophylaxis protocol with warfarin after radiofrequency catheter ablation of infarct-related ventricular tachycardia. J Cardiovasc Electrophysiol 2018;29:584–590.

S10.1.2.3. Patel AA, Clyne CA, Henyan NN, et al. The use of protamine after radiofrequency catheter ablation: a pilot study. J Interv Card Electrophysiol 2007;18:155–158.

S10.1.2.4. Ghannam M, Chugh A, Dillon P, et al. Protamine to expedite vascular hemostasis after catheter ablation of atrial fibrillation: a randomized controlled trial. Heart Rhythm 2018;15:1642–1647.

S10.1.2.5. Calkins H, Epstein A, Packer D, et al; Cooled RF Multi Center Investigators Group. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. J Am Coll Cardiol 2000;35:1905–1914.

S10.1.2.6. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007;357:2657–2665.

S10.1.2.7. Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol 2010;21:47–53.

S10.1.2.8. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31–40.

S10.1.2.9. Al-Khatib SM, Daubert JP, Anstrom KJ, et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol 2015;26:151–157.

S10.1.2.10. Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol 2016;67:674–683.

S10.1.2.11. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;375:111–121.

S10.1.2.12. Kuck KH, Tilz RR, Deneke T, et al; SMS Investigators. Impact of substrate modification by catheter ablation on implantable cardioverter-defibrillator interventions in patients with unstable ventricular arrhythmias and coronary artery disease: results from the multicenter randomized controlled SMS (Substrate Modification Study). Circ Arrhythm Electrophysiol 2017;10:e004422.

10.2. Incidence and Management of Complications

Table 10 Major complications of ventricular arrhythmia ablation in patients with structural heart disease

Complication	Incidence	Mechanisms	Presentation	Prevention	Treatment	Ref.
In-hospital mortality	0%–3%	VT recurrence, heart failure, complications of catheter ablation	Not applicable	Correct electrolyte disturbances and optimize medical status before ablation	—	S10.2.1–S10.2.5
Long-term mortality	3%–35% (12–39 months of follow-up)	VT recurrence and progression of heart failure	Cardiac nonarrhythmic death (heart failure) and VT recurrence	Identification of patients with indication for heart transplantation	—	S10.2.2–S10.2.5
Neurological complication (stroke, TIA, cerebral hemorrhage)	0%–2.7%	Emboli from left ventricle, aortic valve, or aorta; cerebral bleeding	Focal or global neurological deficits	Careful anticoagulation control; ICE can help detection of thrombus formation, and of aortic valve calcification; TEE to assess aortic arch	Thrombolytic therapy	S10.2.1–S10.2.5
Pericardial complications: cardiac tamponade, hemopericardium, pericarditis	0%–2.7%	Catheter manipulation, RF delivery, epicardial perforation	Abrupt or gradual fall in blood pressure; arterial line is recommended in ablation of complex VT	Contact force can be useful, careful in RF delivery in perivenous foci and RVOT	Pericardiocentesis; if necessary, surgical drainage, reversal heparin; steroids and colchicine in pericarditis	S10.2.1–S10.2.5
AV block	0%–1.4%	Energy delivery near the conduction system	Fall in blood pressure and ECG changes	Careful monitoring when ablation is performed near the conduction system; consider cryoablation	Pacemaker; upgrade to a biventricular pacing device might be necessary	S10.2.1–S10.2.4
Coronary artery damage/MI	0.4%–1.9%	Ablation near coronary artery, unintended coronary damage during catheter manipulation in the aortic root or crossing the aortic valve	Acute coronary syndrome; confirmation with coronary catheterization	Limit power near coronary arteries and avoid energy delivery <5 mm from coronary vessel; ICE is useful to visualize the coronary ostium	Percutaneous coronary intervention	S10.2.1–S10.2.5
Heart failure/ pulmonary edema	0%–3%	External irrigation, sympathetic response due to ablation, and VT induction	Heart failure symptoms	Urinary catheter and careful attention to fluid balance and diuresis, optimize clinical status before ablation, reduce irrigation volume if possible (decrease flow rates or use closed irrigation catheters)	New/increased diuretics	S10.2.2–S10.2.5

(*Continued*)

Table 10 (*Continued*)

Complication	Incidence	Mechanisms	Presentation	Prevention	Treatment	Ref.
Valvular injury	0%–0.7%	Catheter manipulation, especially retrograde crossing the aortic valve and entrapment in the mitral valve; energy delivery to subvalvular structures, including papillary muscle	Acute cardiovascular collapse, new murmurs, progressive heart failure symptoms	Careful catheter manipulation; ICE can be useful for identification of precise location of energy delivery	Echocardiography is essential in the diagnosis; medical therapy, including vasodilators and dobutamine before surgery; IABP is useful in acute mitral regurgitation and is contraindicated in aortic regurgitation	S10.2.2–S10.2.5
Acute periprocedural hemodynamic decompensation, cardiogenic shock	0%–11%	Fluid overloading, general anesthesia, sustained VT	Sustained hypotension despite optimized therapy	Close monitoring of fluid infusion and hemodynamic status -Optimize medical status before ablation -pLVAD -Substrate mapping preferred, avoid VT induction in higher-risk patients	Mechanical HS	S10.2.2–S10.2.6
Vascular injury: hematomas, pseudoaneurysm, AV fistulae	0%–6.9%	Access to femoral arterial and catheter manipulation	Groin hematomas, groin pain, fall in hemoglobin	Ultrasound-guided access	Ultrasound-guided compression, thrombin injection, and surgical closure	S10.2.1–S10.2.5
Overall major complications with SHD	3.8%–11.24%					S10.2.1–S10.2.5
Overall all complications	7%–14.7%					S10.2.3,S10.2.7, S10.2.8

AV = atrioventricular; ECG = electrocardiogram; HS = hemodynamic support; IABP = intra-aortic balloon pump; ICE = intracardiac echocardiography; MI = myocardial infarction; pLVAD = percutaneous left ventricular assist device; RF = radiofrequency; RVOT = right ventricular outflow tract; SHD = structural heart disease; TEE = transesophageal echocardiography; TIA = transient ischemic attack; VT = ventricular tachycardia.

References

S10.2.1. Palaniswamy C, Kolte D, Harikrishnan P, et al. Catheter ablation of postinfarction ventricular tachycardia: ten-year trends in utilization, in-hospital complications, and in-hospital mortality in the United States. Heart Rhythm 2014;11:2056–2063.

S10.2.2. Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008;118:2773–2782.

S10.2.3. Calkins H, Epstein A, Packer D, et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. J Am Coll Cardiol 2000;35:1905–1914.

S10.2.4. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007; 357:2657–2665.

S10.2.5. Kuck KH, Schaumann A, Eckardt L, et al; VTACH Study Group. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet 2010;375:31–40.

S10.2.6. Santangeli P, Muser D, Zado ES, et al. Acute hemodynamic decompensation during catheter ablation of scar-related ventricular tachycardia: incidence, predictors, and impact on mortality. Circ Arrhythm Electrophysiol 2015;8:68–75.

S10.2.7. Katz DF, Turakhia MP, Sauer WH, et al. Safety of ventricular tachycardia ablation in clinical practice: findings from 9699 hospital discharge records. Circ Arrhythmia Electrophysiol 2015;8:362–370.

S10.2.8. Santangeli P, Frankel DS, Tung R, et al. Early mortality after catheter ablation of ventricular tachycardia in patients with structural heart disease. J Am Coll Cardiol 2017;69:2105–2115.

10.3. Hemodynamic Deterioration and Proarrhythmia

Recommendation for echocardiography after VA ablation			
COR	LOE	Recommendation	Reference
I	C-LD	**1. Echocardiography should be performed in case of hemodynamic deterioration post-VT ablation to assess for pericardial effusion and cardiac tamponade.**	S10.3.1

Reference

S10.3.1. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Circulation 1997;95:1686–1744.

10.4. Follow-up of Patients Post Catheter Ablation of Ventricular Tachycardia

Recommendation for noninvasive programmed stimulation after catheter ablation of VT			
COR	LOE	Recommendation	References
IIa	B-NR	1. Noninvasive programmed stimulation can be useful in the several days following VT catheter ablation to inform further management, including ICD programming, predicting the risk of VT recurrence, and/or considering a repeat VT catheter ablation.	S10.4.1,S10.4.2




Figure 13 Factors influencing outcomes post VA ablation. ICD = implantable cardioverter defibrillator; LVAD = left ventricular assist device; VA = ventricular arrhythmia; VT = ventricular tachycardia.

References

S10.4.1. Frankel DS, Mountantonakis SE, Zado ES, et al. Noninvasive programmed ventricular stimulation early after ventricular tachycardia ablation to predict risk of late recurrence. J Am Coll Cardiol 2012; 59:1529–1535.

S10.4.2. Oloriz T, Baratto F, Trevisi N, et al. Defining the outcome of ventricular tachycardia ablation: timing and value of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2018;11:e005602.

Section 11 Training and Institutional Requirements and Competencies

This section contains the general training and institutional requirements with an emphasis on lifelong learning, professionalism, and acquisition and maintenance of knowledge and skills. In addition, institutional requirements for specific procedures are reviewed.

11.1. Training Requirements and Competencies for Catheter Ablation of Ventricular Arrhythmias

Recommendation for training requirements and competencies for catheter ablation of VA		
COR	LOE	Recommendation
I	C-EO	1. For clinical cardiac electrophysiologists who perform catheter ablation for VAs, appropriate advanced training and continued lifelong learning is recommended.

11.2. Institutional Requirements for Catheter Ablation of Ventricular Tachycardia

Recommendations for institutional requirements for catheter ablation of VT		
COR	LOE	Recommendations
I	C-EO	1. Patients with certain underlying medical conditions and comorbidities undergoing complex VA ablations who are deemed to have increased procedural risk should undergo procedures in a hospital-based electrophysiology laboratory.
I	C-EO	2. Onsite interventional cardiology expertise is recommended for electrophysiology procedures requiring coronary imaging to delineate coronary anatomy for epicardial ablation, aortography to delineate coronary ostia for SV VT ablation, and need for placement of HS devices.
I	C-EO	3. Onsite cardiothoracic surgical backup is recommended for electrophysiology procedures requiring pericardial access due to the potential need for emergent sternotomy and cardiopulmonary bypass.
I	C-EO	4. Availability of anesthesia personnel is recommended for all patients undergoing catheter ablation of VAs.

Section 12 Future Directions

This section summarizes ongoing trials and the need for prospective evaluation of different clinical problems. It further reviews recent advances and limitations of various mapping techniques and addresses unanswered questions requiring future investigations.

Appendix

Supplementary Data

Supplementary data (Appendix 3) and interview video associated with this article can be found in the online version at https://doi.org/10.1016/j.hrthm.2019.03.014.

Appendix 1 Author disclosure table

Writing group member	Employment	Honoraria/Speaking/ Consulting	Speakers' bureau	Research*	Fellowship support*	Ownership/Partnership/ Principal/Majority stockholder	Stock or stock options	Intellectual property/ Royalties	Other
Edmond M. Cronin, MB, BCh, BAO, FHRS, CCDS, CEPS-A (Chair)	Hartford Hospital, Hartford, Connecticut	None	None	None	None	None	None	None	None
Frank M. Bogun, MD (Vice-Chair)	University of Michigan, Ann Arbor, Michigan	None	None	None	None	None	None	None	None
Philippe Maury, MD (EHRA Chair)	University Hospital Rangueil, Toulouse, France	None	None	None	None	None	None	None	None
Petr Peichl, MD, PhD (EHRA Vice-Chair)	Institute for Clinical and Experimental Medicine, Prague, Czech Republic	1: Abbott; 1: Biosense Webster; 1: BIOTRONIK	None	None	None	None	None	None	None
Minglong Chen, MD, PhD, FHRS (APHRS Chair)	Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China	None	None	None	None	None	None	None	0: APHRS Board Member
Narayanan Namboodiri, MBBS, MD (APHRS Vice-Chair)	Sree Chitra Institute for Medical Sciences and Technology, Thiruvananthapuram, India	None	None	None	None	None	None	None	None
Luis Aguinaga, MD, PhD, FESC, FACC (LAHRS Chair)	Centro Privado de Cardiología, Tucuman, Argentina	None	None	None	None	None	None	None	None
Luiz Roberto Leite, MD, PhD, FHRS (LAHRS Vice-Chair)	Instituto Brasília de Arritmia, Brasília, Brazil	None	1: Boehringer Ingelheim	None	None	None	None	None	None
Sana M. Al-Khatib, MD, MHS, FHRS, CCDS	Duke University Medical Center, Durham, North Carolina	None	None	None	None	None	None	None	None
Elad Anter, MD	Beth Israel Deaconess Medical Center, Boston, Massachusetts	2: Itamar Medical; 3: Boston Scientific; 4: Biosense Webster	None	None	None	None	None	None	None
Antonio Berruezo, MD, PhD	Heart Institute, Teknon Medical Center, Barcelona, Spain	1: Biosense Webster	1: Biosense Webster	2: Biosense Webster	None	None	None	None	None
David J. Callans, MD, FHRS, CCDS	University of Pennsylvania, Philadelphia, Pennsylvania	1: Abbott Laboratories; 1: BIOTRONIK; 1: Medtronic; 1: Wolters Kluwer; 2: Boston Scientific	None	4: NIH	2: BIOTRONIK; 2: Boston Scientific; 4: Abbott; 4: Biosense Webster; 4: Medtronic	None	None	None	1: Acutus Medical; 1: AtriCure; 1: Impulse Dynamics; 1: Thermedical; 3: Bayer

(*Continued*)

Appendix 1 (*Continued*)

Writing group member	Employment	Honoraria/Speaking/ Consulting	Speakers' bureau	Research*	Fellowship support*	Ownership/Partnership/ Principal/Majority stockholder	Stock or stock options	Intellectual property/ Royalties	Other
Mina K. Chung, MD, FHRS	Cleveland Clinic, Cleveland, Ohio	2: ABIM	None	5: AHA; 5: NIH	None	None	None	1: Elsevier; 1: Up to Date	0: ACC (EP Section Leadership Council member); 0: AHA (Chair, ECG & Arrhythmias Committee; Member, Clinical Cardiology Leadership Committee; Member, Committee on Scientific Sessions Programming); 0: Amarin (Data monitoring committee member); 0: BIOTRONIK; 2: AHA (Associate Editor, *Circulation Arrhythmia & Electrophysiology*)
Phillip Cuculich, MD	Washington University School of Medicine, St. Louis, Missouri	2: Medtronic	None	None	None	None	None	None	None
Andre d'Avila, MD, PhD	Hospital Cardiologico SOS Cardio, Florianopolis, Brazil	None	None	None	None	None	None	None	None
Barbara J. Deal, MD, FACC	Northwestern University Feinberg School of Medicine, Chicago, Illinois	None	None	None	None	None	None	None	None
Paolo Della Bella, MD	Ospedale San Raffaele, Milan, Italy	2: Biosense Webster; 2: Boston Scientific; 3: Abbott	None	None	2: Medtronic; 3: Abbott Vascular; 3: Biosense Webster; 3: BIOTRONIK; 4: Boston Scientific	None	None	None	None
Thomas Deneke, MD, PhD, FHRS	Herz- und Gefäß-Klinik, Bad Neustadt, Germany	None	None	None	None	None	None	None	None
Timm-Michael Dickfeld, MD, PhD, FACC, FHRS	University of Maryland, Baltimore, Maryland	1: Abbott Laboratories; 1: Biosense Webster; 1: Impulse Dynamics; 1: Philips	None	1: GE Healthcare	None	None	None	None	None
Claudio Hadid, MD	Hospital General de Agudos Cosme Argerich, Buenos Aires, Argentina	None	None	None	None	None	None	None	None
Haris M. Haqqani, MBBS, PhD, FHRS	University of Queensland, The Prince Charles Hospital, Chermside, Australia	0: Abbott Laboratories; 0: Boston Scientific; 0: Medtronic	None	3: Biosense Webster	None	None	None	None	None
G. Neal Kay, MD, CCDS	University of Alabama at Birmingham, Birmingham, Alabama	None	None	None	None	None	None	None	None
Rakesh Latchamsetty, MD, FHRS	University of Michigan, Ann Arbor, Michigan	None	1: BIOTRONIK	None	None	None	None	None	None
Francis Marchlinski, MD, FHRS	University of Pennsylvania, Philadelphia, Pennsylvania	1: Abbott; 1: Biosense Webster; 1: Boston Scientific; 1: Medtronic; 2: BIOTRONIK	None	1: Abbott; 4: Biosense Webster	2: BIOTRONIK; 2: Boston Scientific; 4: Abbott; 4: Biosense Webster; 4: Medtronic	None	None	None	None

(*Continued*)

John M. Miller, MD, FHRS	Indiana University School of Medicine, Krannert Institute of Cardiology, Indianapolis, Indiana	1: Abbott Laboratories; 1: Biosense Webster; 1: Boston Scientific; 1: BIOTRONIK; 1: Medtronic	None	None	3: Biosense Webster; 3: Boston Scientific; 3: Medtronic	None	None	1: Elsevier	None
Akihiko Nogami, MD, PhD	University of Tsukuba, Ibaraki, Japan	1: Abbott Laboratories	None	4: Medtronic	None	None	None	None	None
Akash R. Patel, MD, FHRS, CEPS-P	University of California San Francisco Benioff Children's Hospital, San Francisco, California	None	None	None	None	None	None	None	None
Rajeev Kumar Pathak, MBBS, PhD, FHRS	Australian National University, Canberra Hospital, Canberra, Australia	1: BIOTRONIK	1: Medtronic	None	None	None	None	None	None
Luis C. Saenz Morales, MD	CardioInfantil Foundation, Cardiac Institute, Bogota, Columbia	None	None	None	None	None	None	None	None
Pasquale Santangeli, MD, PhD	University of Pennsylvania, Philadelphia, Pennsylvania	1: Abiome; 1: Baylis Medical; 1: Biosense Webster; 1: Medtronic; 1: Stereotaxis; 2: Abbott Laboratories	None	None	None	None	None	None	None
John L. Sapp, Jr., MD, FHRS	Queen Elizabeth II Health Sciences Centre, Halifax, Canada	1: Abbott Vascular; 1: Biosense Webster; 1: Medtronic	None	4: Abbott Vascular; 5: Biosense Webster	None	None	None	1: Biosense Webster	None
Andrea Sarkozy, MD, PhD, FEHRA	University Hospital Antwerp, University of Antwerp, Antwerp, Belgium	1: Biosense Webster; 1: BIOTRONIK	None	None	None	None	None	None	0: EHRA Board member
Kyoko Soejima, MD	Kyorin University School of Medicine, Tokyo, Japan	2: Abbott Laboratories; 2: Boehringer Ingelheim	3: Medtronic	None	None	None	None	None	None
William G. Stevenson, MD, FHRS	Vanderbilt University Heart and Vascular Center, Nashville, Tennessee	1: Abbott; 1: BIOTRONIK; 1: Boston Scientific; 1: Medtronic	None	None	None	None	None	0: Biosense Webster; 0: Brigham and Women's Hospital	None
Usha B. Tedrow, MD, MS, FHRS	Brigham and Women's Hospital, Boston, Massachusetts	1: Abbott; 1: Biosense Webster; 1: Medtronic	None	None	None	None	None	None	None
Wendy S. Tzou, MD, FHRS	University of Colorado Denver, Aurora, Colorado	1: Abbott; 1: Biosense Webster; 1: BIOTRONIK; 1: Boston Scientific; 1: Medtronic	None	None	None	None	None	None	None
Niraj Varma, MD, PhD	Cleveland Clinic, Cleveland, Ohio	1: BIOTRONIK; 1: Medtronic	None	3: Abbott	None	None	None	None	None
Katja Zeppenfeld, MD, PhD, FESC, FEHRA	Leiden University Medical Center, Leiden, the Netherlands	1: Abbott	None	5: Biosense Webster	3: Biosense Webster	None	None	None	None

Number value: **0** = $0; **1** = ≤ $10,000; **2** = > $10,000 to ≤ $25,000; **3** = > $25,000 to ≤ $50,000; **4** = > $50,000 to ≤ $100,000; **5** = > $100,000.

ABIM = American Board of Internal Medicine; ACC = American College of Cardiology; AHA = American Heart Association; APHRS = Asia Pacific Heart Rhythm Society; EHRA = European Heart Rhythm Association; LAHRS = Latin American Heart Rhythm Society; NIH = National Institutes of Health.

*Research and fellowship support are classed as programmatic support. Sources of programmatic support are disclosed but are not regarded as a relevant relationship with industry for writing group members or reviewers.

Appendix 2 Reviewer disclosure table

Peer reviewer	Employment	Honoraria/Speaking/ Consulting	Speakers' bureau	Research*	Fellowship support*	Ownership/ Partnership/Principal/ Majority stockholder	Stock or stock options	Intellectual property/ Royalties	Other
Samuel J. Asirvatham, MD, FHRS	Mayo Clinic College of Medicine, Rochester, Minnesota	1: Abbott; 1: BIOTRONIK; 1: Boston Scientific; 1: Medtronic	None	None	None	None	None	1: AliveCor	None
Eduardo Back Sternick, MD, PhD	Faculdade Ciências Médicas de Minas, Gerais, Brazil	None	None	None	None	None	None	None	None
Janice Chyou, MD	Northport VA Medical Center, Northport, New York; Agile Health, New York, New York	None	None	None	None	None	None	None	None
Sabine Ernst, MD, PhD	Royal Brompton and Harefield Hospitals, London, England	2: Biosense Webster; 2: Stereotaxis	None	3: Other; 4: Baylis; 4: Spectrum Dynamics	None	None	None	None	None
Guilherme Fenelon, MD, PhD	Hospital Israelita Albert Einstein, Sao Paulo, Sao Paulo, Brazil	1: Libbs	None	None	None	None	None	None	None
Edward P. Gerstenfeld, MD, MS, FACC	University of California, San Francisco, San Francisco, California	1: Abbott Vascular; 1: Biosense Webster; 1: Boston Scientific; 1: Medtronic	None	4: Abbott Vascular; 4: Biosense Webster	None	None	None	None	None
Gerhard Hindricks, MD	Heart Center Leipzig at the University of Leipzig, Leipzig, Germany	None	None	4: Abbott Vascular	None	None	None	None	None
Koichi Inoue, MD, PhD	Sakurabashi-Watanabe Hospital, Osaka, Japan	2: Biosense Webster; 2: Medtronic Japan	None	None	None	None	None	None	None
Jeffrey J. Kim, MD	Baylor College of Medicine, Texas Children's Hospital, Houston, Texas	None	None	None	3: Medtronic	None	None	None	None
Kousik Krishnan, MD, FHRS, FACC	Rush University Medical Center, Chicago, Illinois	1: ZOLL	None	None	None	None	None	None	None
Karl-Heinz Kuck, MD, FHRS	Asklepios Klinik St. Georg, Hamburg, Germany	1: Abbott Vascular; 1: Biosense Webster; 1: Boston Scientific; 1: Edwards Lifesciences; 1: Medtronic	None	None	None	None	None	None	None

(*Continued*)

Martin Ortiz Avalos, MD	Hospital San Angel Inn Universidad, Mexico City, Mexico	None	None	None	None	None	None	None	None
Thomas Paul, MD, FACC, FHRS	Georg August University Medical Center, Gottingen, Germany	None	None	None	None	None	None	None	None
Mauricio I. Scanavacca, MD, PhD	Instituto Do Coracao, Sao Paulo, Brazil	None	None	None	None	None	None	None	None
Roderick Tung, MD, FHRS	The University of Chicago Medicine, Center for Arrhythmia Care, Heart and Vascular Center, Chicago, Illinois	2: Abbott	None	2: Abbott	3: Abbott; 3: Medtronic; 3: Boston Scientific	None	None	None	None
Jamie Voss, MBChB	Middlemore Hospital, Auckland, New Zealand	None	None	None	None	None	None	None	None
Takumi Yamada, MD	University of Alabama at Birmingham, Birmingham, Alabama	1: Nihon Kohden; 2: Abbott; 2: Japan Lifeline	None	None	None	None	None	None	None
Teiichi Yamane, MD, PhD, FHRS	Jikei University School of Medicine, Tokyo, Japan	1: Boehringer Ingelheim; 1: Bristol-Myers Squibb; 2: Abbott Laboratories; 2: Medtronic Japan	None	None	None	None	None	None	None

Number value: 0 = $0; 1 = ≤ $10,000; 2 = > $10,000 to ≤ $25,000; 3 = > $25,000 to ≤ $50,000; 4 = > $50,000 to ≤ $100,000; 5 = > $100,000.

*Research and fellowship support are classed as programmatic support. Sources of programmatic support are disclosed but are not regarded as a relevant relationship with industry for writing group members or reviewers.